Methods for the production of recombinant erwinia asparaginase

Abstract

Methods for producing recombinant Erwinia asparaginase are provided herein that produce asparaginase with high expression levels in the periplasm or cytoplasm of host cells with activity comparable to commercially available asparaginase preparations.

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 62 / 578,305, filed October 27, 2017, which is incorporated herein by reference.

[0002] Sequence Listing This application contains a Sequence Listing that has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The ASCII copy, created on October 16, 2018, is named 38194-749_601_SL.txt and is 71,228 bytes in size. [Background technology]

[0003] Background of the present application L-asparaginase type II from the bacterium Erwinia chrysanthemi, also known as crisantaspase, is indicated in combination with other chemotherapy drugs for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity or subclinical inactivation to native or PEGylated asparaginase from E. coli. It can also be used to treat other neoplastic conditions. Crisantaspase is produced by fermentation of Erwinia chrysanthemi, producing a cell paste that is processed through a series of chromatography and other methods to produce an enzyme preparation that yields the drug substance. When expressed in Erwinia, the crisantaspase preprotein is secreted into the periplasmic space of the cell using the native secretory signal sequence present at its N-terminus. Once localized in the periplasmic space, the signal sequence is cleaved to produce a tetramer or a mature monomer that can naturally fuse to form active crisantaspase. In some cases, recombinant crisantaspase has been expressed in E. coli using fusion with various secretory signal peptides from heterologous sources. Summary of the Invention

[0004] Methods for producing recombinant type II asparaginase are provided herein. In some embodiments, the methods include culturing Pseudomonadales host cells in a culture medium and expressing recombinant asparaginase in the cytoplasm of the Pseudomonadales host cells from an expression construct comprising a nucleic acid encoding the recombinant asparaginase, wherein the recombinant asparaginase is produced in the cytoplasm at a yield of about 20% to about 40% TCP-soluble asparaginase. In some embodiments, the recombinant asparaginase is produced in the cytoplasm at a yield of about 10 g / L to about 25 g / L. In some embodiments, the methods further include measuring the activity of the amount of soluble recombinant type II asparaginase produced using an activity assay. In some embodiments, the nucleic acid encoding the recombinant asparaginase is optimized for expression in the host cell. In some embodiments, the recombinant asparaginase is Erwinia chrysanthemi L-asparaginase type II (crisantaspase). In some embodiments, the nucleic acid encoding the recombinant asparaginase is at least 85% homologous to SEQ ID NO: 1. In some embodiments, the recombinant asparaginase is at least 85% homologous to SEQ ID NO:2. In some embodiments, expression of the recombinant asparaginase is induced by the addition of IPTG to the culture medium. In some embodiments, IPTG is at a concentration of about 0.05 mM to about 2.5 mM in the culture medium. In some embodiments, expression of the recombinant asparaginase is induced when the Pseudomonad host cell grows to a wet cell weight of about 0.1 g / g to about 0.5 g / g. In some embodiments, the Pseudomonadales host cell is cultured at a pH of about 5.0 to about 8.0. In some embodiments, the Pseudomonadales host cell is cultured at a temperature of about 22°C to about 33°C. In any embodiment, the Pseudomonadales host cell herein is a Pseudomonas fluorescens cell. In some embodiments, the Pseudomonadales host cell is deficient in expression of one or more asparaginases.In some embodiments, the Pseudomonadales host cell is deficient in expression of one or more native asparaginases. In some embodiments, the underexpressed native asparaginase is a type I asparaginase. In some embodiments, the underexpressed native asparaginase is a type II asparaginase. In some embodiments, the Pseudomonadales host cell is deficient in expression of one or more proteases. In some embodiments, the Pseudomonadales host cell overexpresses one or more folding modulators. In some embodiments, the Pseudomonadales host cell is deficient in expression of one or more native asparaginases, deficient in expression of one or more proteases, and / or overexpresses one or more folding modulators.

[0005] In some embodiments, the method includes culturing Pseudomonadales host cells in a culture medium and expressing recombinant asparaginase in the periplasm of the Pseudomonadales host cells from an expression construct comprising a nucleic acid encoding the recombinant asparaginase, wherein the recombinant asparaginase is a TCP-soluble asparaginase (e.g., a monomeric asparaginase) produced in the periplasm at a yield of about 20% to about 40%. In some embodiments, the recombinant asparaginase is produced in the periplasm at a yield of about 5 g / L to about 20 g / L. In some embodiments, the method further includes measuring the activity of the amount of recombinant type II asparaginase produced using an activity assay. In some embodiments, the nucleic acid encoding the recombinant asparaginase is optimized for expression in the host cell. In some embodiments, the recombinant asparaginase is Erwinia chrysanthemi type II L-asparaginase (crisantaspase). In some embodiments, the nucleic acid encoding the recombinant asparaginase is at least 85% identical to SEQ ID NO: 1. In some embodiments, the recombinant asparaginase has an amino acid sequence at least 85% identical to SEQ ID NO:2. In some embodiments, expression of the recombinant asparaginase is induced by the addition of IPTG to the culture medium. In some embodiments, IPTG is at a concentration of about 0.05 mM to about 2.5 mM in the culture medium. In some embodiments, expression of the recombinant asparaginase is induced when the Pseudomonadales host cell has grown to about 0.05 g / g to about 0.5 g / g wet weight. In some embodiments, the Pseudomonadales host cell is cultured at a pH of about 5.0 to about 8.0. In some embodiments, the Pseudomonadales host cell is cultured at a temperature of about 22°C to about 33°C. In some embodiments, the Pseudomonadales host cell is a Pseudomonas fluorescens cell. In some embodiments, the Pseudomonadales host cell is deficient in expression of one or more native asparaginases.In some embodiments, the incompletely expressed native asparaginase is a type I asparaginase. In some embodiments, the incompletely expressed native asparaginase is a type II asparaginase. In some embodiments, the Pseudomonadales host cell is deficient in expression of one or more proteases. In some embodiments, the Pseudomonadales host cell overexpresses one or more folding modulators. In some embodiments, the expression construct comprises a secretion leader. In some embodiments, the secretion leader is selected from the group consisting of Pseudomonadales secretion leaders FlgI, Ibps31A, PbpA20V, DsbC, 8484, and 5193. In some embodiments, the secretion leader directs translocation of the produced recombinant asparaginase to the periplasm of the Pseudomonad host cell. In some embodiments, the method further comprises comparing the measured activity of the produced recombinant type II asparaginase to the activity measured with the same amount of a control type II asparaginase using the same activity assay. In some embodiments, the control type II asparaginase comprises an Erwinia type II asparaginase commercially approved for use in patients in at least one country. In some embodiments, the recombinant type II asparaginase produced is selected for use in patients having about 80% to about 120% of the activity of a type II asparaginase control sample. In some embodiments, the recombinant type II asparaginase is modified to increase its half-life in patients. In embodiments, the host cell is selected from at least one of the following: a host cell lacking HslUV protease, a host cell lacking PrtB protease, a host cell lacking Prc protease, a host cell lacking DegP protease, a host cell lacking AprA protease, a host cell lacking Lon protease, a host cell lacking La protease, a host cell lacking DegP1, a host cell lacking DegP2, and a host cell overexpressing DegP2 S219A.

[0006] Incorporation by Reference All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

[0007] The novel features of the present disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings of which: [Brief explanation of the drawings]

[0008] [Figure 1]Figure 1. SDS-CGE gel-like image - Tier 1 expression plasmid screen. Crisantaspase small-scale growth whole broth sonicate soluble samples from DC454 (top panel) and DC441 (bottom panel) were analyzed by reducing SDS-CGE. The leftmost lane shows molecular weight marker ladder 1 (top panel MW ladder 48 KD, 29 KD; bottom panel MW ladder 48 KD, 29 KD, 21 KD), and the rightmost lane shows the same ladder. From left to right (lanes 1 to 46), starting immediately to the right of Ladder 1, are lanes showing the expression patterns observed when the following secretion leader peptides are fused to the N-terminus (high RBS unless otherwise indicated) of the crisantaspase protein: leaderless; DsbD; leaderA; DsbA; DsbA-medium RBS; Azu; Azu-medium RBS; Lao; Ibp-S31A; TolB; DC432 null (wild-type host carrying the plasmid-only vector) Main strain); Tpr; Ttg2C; FlgI; CupC2; CupB2; Pbp; PbpA20V; DsbC; Leader B; Leader C; DC432 null; Leader D; Leader E; Leader F; Leader G; Leader H; PorE; Leader I; Leader J; Leader K; Leader L; DC432 null; Leader M; Leader N; Leader O; 5193; Leader P; Leader Q; Leader R; 8484; Leader S; Leader T; DC432 null. The arrow on the right side of the gel image indicates the migration of the crisantaspase target protein (35 kDa).

[0009] [Figure 2] Figure 2. Crisantaspase example sequence. An exemplary nucleic acid sequence encoding crisantaspase (SEQ ID NO: 2) is shown along with the corresponding amino acid sequence (SEQ ID NO: 1). The complete nucleic acid sequence, including the SapI restriction site, is also shown (SEQ ID NO: 63).

[0010] [Figure 3] Figure 3. Expression plasmid map. The map shows examples of plasmids for expressing crisantaspase in P. fluorescens.

[0011] [Figure 4]Figure 4. SDS-CGE gel-like image - Shake flask expression analysis. Expression at different growth conditions, as measured by soluble reducing capillary gel electrophoresis (SDS-CGE), is shown. From left to right, lanes show the expression patterns observed in the following samples: Ladder 1 (molecular weight markers 68, 48, 29, 21, and 16 KD); STR55987 at I0 (cytoplasmic expression, leaderless); STR55987 at I24 (cytoplasmic expression, leaderless); STR55987 at I24 (cytoplasmic expression, leaderless); STR55987 at I24 (cytoplasmic expression, leaderless); STR55979 at I0 (leader O); STR55979 at I24 (leader O); STR55979 at I24 (leader O); leader O); STR55979 (leader O) at I24; STR55980 (8484 leader) at I0; STR55980 (8484 leader) at I24; STR55980 (8484 leader) at I24; STR55980 (8484 leader) at I24; STR55982 (null plasmid) at I0; STR55982 (null plasmid) at I24; STR55982 (null plasmid) at I24; STR55982 (null plasmid) at I24; Ladder 2 (same markers as Ladder 1); Sigma E. coli AspG 1,000 ug / ml (standard E. coli Asp2); Sigma E. coli AspG 500 ug / ml; Sigma E. coli AspG 250 ug / ml; Sigma E. coli AspG 125 ug / ml; Sigma E. coli AspG 62.5 ug / ml; and Ladder 3 (same markers as Ladder 1), where the I0 sample is taken at induction and the I24 sample is taken 24 hours after induction.

[0012] [Figure 5] Figure 5. Growth of STR55978 - 2 liter fermentation. Growth as measured by wet cell weight under different growth conditions (conditions 1-8) is shown as a function of fermentation time.

[0013] [Figure 6]Figure 6. STR55978 protein production - 2 liter fermentation. Recombinant asparaginase titer measured by reduced soluble SDS-CGE is shown.

[0014] [Figure 7] Figure 7. Mass spectrometry data - shake flask expression analysis. Intact mass of expressed recombinant asparaginase is shown. DETAILED DESCRIPTION OF THE INVENTION

[0015] Detailed Description of the Invention overview Disclosed herein are methods for producing soluble recombinant L-asparaginase type II from Erwinia chrysanthemi, also known as crisantaspase, in Pseudomonas host cells. High levels of crisantaspase production as a percentage of total cellular protein, e.g., up to 40% TCP crisantaspase, e.g., crisantaspase monomers capable of forming active tetramers without detectable degradation, are described herein. High titers of crisantaspase production, e.g., up to 20 grams per liter of crisantaspase, e.g., crisantaspase monomers capable of forming active tetramers without detectable degradation, can be obtained using the methods of the present invention. Host cells for producing crisantaspase include, but are not limited to, Pseudomonas, e.g., Pseudomonas fluorescens. Crisantaspase expression constructs can be codon-optimized depending on the host strain selected.

[0016] Nucleic acid constructs useful in the methods of the present invention can encode a crisantaspase gene operably linked to a nucleic acid sequence encoding a secretion signal (secretion leader), such as a periplasmic secretion leader native to P. fluorescens, that results in expression of a secretion leader-crisantaspase fusion protein. In some embodiments, the periplasmic secretion leader comprises one or more of FlgI, 8484, DsbC, Ibp-S31A, or 5193. In embodiments, the host cell has a mutation in one or more protease-encoding genes that results in inactivation of the protease. It is understood that the mutation that results in inactivation of the protease or any other gene product can be any type of mutation known in the art to cause protein inactivation or prevent protein expression, including, but not limited to, substitution, insertion, or deletion mutations in either the coding or regulatory sequences of the gene. It is understood that overexpression of the folding modulator can be achieved using any method, such as plasmid expression or chromosomal integration of the folding modulator gene. In an embodiment, the host cell has at least one protease inactivation and overexpresses at least one folding modulator.

[0017] As is known to those skilled in the art, an amino acid sequence can be encoded by different nucleotide sequences due to redundancy in the genetic code. Thus, the present invention includes the use of peptides or proteins having the same amino acid sequence but encoded by different nucleotide sequences.

[0018] In embodiments, the secretory leader transports soluble crisantaspase to the periplasm of the host cell. In other embodiments, crisantaspase is retained in the cytoplasm. In embodiments, the crisantaspase purification process does not require crisantaspase solubilization and subsequent refolding. In embodiments, at least a portion of the crisantaspase is not expressed in inclusion bodies. In embodiments, the recombinant crisantaspase is expressed without any peptide tag for purification and does not require additional processing during purification. In embodiments in which the secretory leader is fused to an asparaginase protein, the secretory leader is efficiently processed from the solubly expressed crisantaspase. In other embodiments, the expression plasmid for periplasmic production of crisantaspase does not utilize any antibiotic resistance marker gene for selection and maintenance, thus eliminating the complex process for subsequent removal of plasmid DNA required for biopharmaceutical production. In other embodiments, the fermentation conditions are scalable for large-scale production. The methods provided herein produce high levels of soluble and / or active crisantaspase.

[0019] In embodiments, the present invention provides methods for the cytoplasmic production of recombinant proteins in high-yield, soluble form, where the recombinant protein is produced in the periplasm at low yield in its native host. In its native host, Erwinia chrysanthemi, crisantaspase is produced in the periplasm. The present invention provides methods that enable the production of high levels of soluble and / or active crisantaspase in the cytoplasm of host cells. In embodiments, the methods provided herein result in high levels of soluble and / or active crisantaspase in the cytoplasm of Pseudomonadales, Pseudomonad, Pseudomonas, or Pseudomonas fluorescens host cells.

[0020] Cytoplasmic production of recombinant proteins can facilitate purification. For larger proteins (e.g., the crisantaspase tetramer is a 35KD x 4, or 140KD complex), a lower percent recovery from the periplasmic space is expected using periplasmic release compared to total release from the cytoplasm. Furthermore, incomplete or improper processing of secretory leaders in periplasmically expressed proteins can result in unwanted product-associated impurities that must be separated from the target protein, resulting in an overall lower process yield.

[0021] Asparaginase Asparaginase, including type II L-asparaginase, is an enzyme that catalyzes the hydrolysis of L-asparagine to L-aspartic acid and ammonia (L-asparagine + HO = L-aspartic acid + NH). Type II L-asparaginase is used as part of multidrug chemotherapy regimens to treat ALL and some other cancers. While normal cells can synthesize asparagine, certain cancer cells cannot synthesize asparagine due to the lack of asparagine synthetase. Therefore, administration of asparaginase to a patient results in the hydrolysis of soluble asparagine and circulating asparagine. This can lead to the death of cancer cells, which has less effect on normal cells. Asparaginase is described, for example, in Pritsa and Kyriakidis, 2002, "L-Asparaginase: Structure, Properties, and Anti-Tumor Activity," in Drug Discovery and Design: Medical Aspects, IOS Press, Matsoukas, J., and Mavromoustakos, T., eds., incorporated herein by reference.

[0022] Erwinaze® (Biologics License Application 125359) is an Erwinia chrysanthemi L-asparaginase type II product commercially approved in the United States for all treatments in patients. Its active ingredient is Erwinia chrysanthemi L-asparaginase type II (see Erwinaze® package insert, incorporated herein by reference).

[0023] In embodiments, Erwinia chrysanthemi type II asparaginase (e.g., the amino acid sequence set forth herein in SEQ ID NO: 1 or any of SEQ ID NOs: 35-49, including the secretory leader sequence) is produced using the methods of the present invention. In some embodiments, the Erwinia chrysanthemi type II asparaginase has an amino acid sequence that is at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1. The asparaginase is a "pegylated L-asparaginase," as described, for example, in U.S. Patent Application No. US2016 / 0060613, which is incorporated by reference in its entirety and includes common structural features of known L-asparaginases from bacterial sources. According to US2016 / 0060613, all are homotetramers with four active sites between two adjacent N- and C-terminal domains, all have high similarity in tertiary and quaternary structure, and the catalytic site sequence of L-asparaginase is highly conserved among Erwinia chrysanthemi, Erwinia carotovora, and E. coli L-asparaginase II. In one embodiment, the protein is Erwinia chrysanthemi L-asparaginase having the sequence of SEQ ID NO:1. This L-asparaginase, either with or without a signal peptide and / or leader sequence, has been disclosed as Erwinia chrysanthemi NCPPB 1066 (Genbank Accession No. CAA32884; see, e.g., Minton, et al., 1986, "Nucleotide sequence of the Erwinia chrysanthemi NCPPB 1066 L-asparaginase gene," Gene 46(1), 25-35, each of which is incorporated herein by reference in its entirety).

[0024] In embodiments, the crisantaspase produced using the methods of the present invention is a variant of an Erwinia chrysanthemi asparaginase L-asparaginase type II enzyme, wherein the variant has about 80% to about 120%, or more, about 85% to about 120%, about 90% to about 120%, about 95% to about 120%, about 98% to about 120%, about 100% to about 120%, about 80% to about 100%, about 80% to about 90%, about 85% to about 115%, about 90% to about 110%, about 95% to about 155%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, or at least about 100% of the L-asparaginase type II activity of the Erwinia chrysanthemi L-asparaginase type II enzyme.

[0025] In embodiments, the Erwinia chrysanthemi asparaginase type II is encoded by a nucleic acid having the sequence, wherein the codons are optimized as desired for expression in a host cell. In some embodiments, the Erwinia chrysanthemi asparaginase type II is encoded by a nucleic acid having the sequence of SEQ ID NO: 2. In some embodiments, the Erwinia chrysanthemi asparaginase type II is encoded by a nucleic acid having a sequence that is at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2.

[0026] In embodiments, the type II asparaginase produced using the methods of the present invention is encoded by a nucleic acid sequence that is at least about 70% identical to a wild-type Erwinia chrysanthemi asparaginase gene. In embodiments, the asparaginase has an amino acid sequence that is at least about 70% identical to a wild-type Erwinia chrysanthemi asparaginase. In some embodiments, the recombinant asparaginase has a nucleic acid sequence that is at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a wild-type Erwinia chrysanthemi asparaginase nucleic acid sequence. In some embodiments, the recombinant asparaginase has an amino acid sequence encoded by a nucleic acid that is at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a wild-type Erwinia chrysanthemi asparaginase nucleic acid sequence. "Identity" or "homology," expressed as a percentage herein, describes a measure of similarity between two sequences. In some embodiments, the degree of identity between two sequences is determined using computer programs and mathematical algorithms known in the art. Such algorithms that calculate percent sequence identity (homology) generally account for sequence gaps and mismatches across the comparison region. For example, the BLAST (e.g., BLAST 2.0) search algorithm (see, e.g., Altschul et al., J. Mol. Biol. 215:403 (1990), publicly available through NCBI) has the following exemplary search parameters: Mismatch -2; Gap Open 5; Gap Extension 2. For polypeptide sequence comparison, the BLASTP algorithm is typically used in combination with a scoring matrix such as PAM100, PAM 250, BLOSUM 62, or BLOSUM 50.FASTA (e.g., FASTA2 and FASTA3) and SSEARCH sequence comparison programs are also used to quantify the degree of identity (Pearson et al., Proc. Natl. Acad. Sci. USA 85:2444 (1988); Pearson, Methods Mol. Biol. 132:185 (2000); and Smith et al., J. Mol. Biol. 147:195 (1981)).

[0027] Crisantaspase, a recombinant type II asparaginase from Erwinia chrysanthemi, is also known as Erwinase® and Erwinaze®. Recombinant asparaginase derived from E. coli is known under the names Colaspase®, Elspar®, Kidrolase®, Leunase®, and Spectrila®. Pegaspargase® is the name for the pegylated version of E. coli asparaginase. Crisantaspase is administered intravenously, intramuscularly, or subcutaneously to patients with acute lymphoblastic leukemia, acute myeloid leukemia, and non-Hodgkin's lymphoma.

[0028] Commercially approved asparaginase type II products for patient use can be identified by accessing product information for asparaginase products available from national drug approval agencies. For example, product information and approval records are publicly available in the United States for Elspar (E. coli L-asparagine amidohydrolase, type EC-2; BLA#101063) and Erwinaze® (asparaginase Erwinia chrysanthemi, BLA#125359), for example, from the U.S. Food and Drug Administration (10903 New Hampshire Avenue, Silver Spring, MD 20993, and online at the FDA website), which are incorporated herein by reference. European product information is available from the European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5EU, United Kingdom, and online at the EMA website (see, e.g., Oncaspar: EPAR Product Information for PEGylated E. coli L-asparaginase, first published January 19, 2016; Spectrila: EPAR Product Information, first published January 28, 2016; and List of Nationally Approved Medicinal Products, April 27, 2016, European Medicines Agency, each of which is incorporated herein by reference).

[0029] In some embodiments, modified versions of crisantaspase are generated. Generally, with respect to amino acid sequences, the term "modification" includes substitution, insertion, extension, deletion, and derivatization, alone or in combination. In certain embodiments, the modified version of crisantaspase has enhanced properties, such as an increased half-life when administered to a patient. In some embodiments, the modified version of crisantaspase with an increased half-life is pegylated. In some embodiments, the crisantaspase may include one or more modifications of "non-essential" amino acid residues. In this context, a "non-essential" amino acid residue is a residue that can be altered, e.g., deleted, substituted, or derivatized, in the new amino acid sequence without abolishing or substantially reducing the activity (e.g., enzymatic activity) of the crisantaspase (e.g., an analog crisantaspase). In some embodiments, the crisantaspase may include one or more modifications of "essential" amino acid residues. In this context, an "essential" amino acid residue is a residue that, when altered, e.g., deleted, substituted, or derivatized, in the new amino acid sequence, substantially reduces or abolishes the activity of the reference crisantaspase. In such embodiments in which essential amino acid residues are altered, the modified crisantaspase may possess the desired crisantaspase activity in the manner provided. Substitutions, insertions, and deletions may be at the N- or C-terminus, or internal to the protein. By way of example, the protein may contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more substitutions, both consecutively or spaced apart throughout the peptide molecule. Alone or in combination with substitutions, the peptide may contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more insertions, either consecutively or spaced apart throughout the peptide molecule. Alone or in combination with substitutions and / or insertions, the peptide may also contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more deletions, again either consecutively or spaced apart throughout the peptide molecule.The peptides may also contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acid additions, either alone or in combination with substitutions, insertions, and / or deletions.

[0030] Substitutions include conservative amino acid substitutions. A "conservative amino acid substitution" is one in which an amino acid residue is replaced with an amino acid residue having a similar side chain or physicochemical properties (e.g., electrostatic, hydrogen-bonding, isosteric, hydrophobic characteristics). The amino acid may be natural or non-natural. Families of amino acid residues with similar side chains are known in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, methionine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Substitutions may also include non-conservative changes.

[0031] Expression system In some cases, the methods herein include expressing recombinant crisantaspase from an expression construct in a Pseudomonas host cell. In some cases, the expression construct is a plasmid. In some embodiments, the plasmid encoding the crisantaspase sequence contains a selectable marker, and host cells maintaining the plasmid are grown under selective conditions. In some embodiments, the plasmid does not contain a selectable marker. In some embodiments, the expression construct is integrated into the host cell genome. In some embodiments, the expression construct encodes crisantaspase fused to a secretion signal that directs the crisantaspase to the periplasm. In some embodiments, the secretion signal is cleaved in the host cell. In some embodiments, the expression construct does not encode a secretion signal, and crisantaspase is directed to the cytoplasm.

[0032] Methods for expressing heterologous proteins in host strains, including Pseudomonas host strains, containing regulatory sequences (e.g., promoters, secretion leaders, and ribosome binding sites) useful in the methods of the present invention are described, for example, in U.S. Pat. No. 7,618,799, entitled "Bacterial leader sequences for increased expression," U.S. Pat. No. 7,985,564, entitled "Expression systems with Sec-system secretion," U.S. Pat. Nos. 9,394,571 and 9,580,719, both entitled "Method for Rapidly Screening Microbial Hosts to Identify Certain Strains with Improved Yield and / or Quality in the Expression of Heterologous Proteins," U.S. Pat. No. 9,453,251, entitled "Expression of Mammalian Proteins in Pseudomonas fluorescens," U.S. Pat. No. 8,603,824, entitled "Process for Improved Protein Expression by Strains," each of which is incorporated herein by reference in its entirety. and U.S. Patent No. 8,530,171, "High Level Expression of Recombinant Toxin Proteins." In embodiments, the secretion leader used in the context of the present invention is a secretion leader disclosed in any of U.S. Patent Nos. 7,618,799, 7,985,564, 9,394,571, 9,580,719, 9,453,251, 8,603,824, and 8,530,171. These patents also describe bacterial host strains useful in the practice of the methods herein that have been engineered to overexpress folding modulators or have introduced heterologous protease mutations to increase heterologous protein expression.

[0033] promoter The promoter used in accordance with the methods herein can be a constitutive promoter or a regulated promoter. Common examples of useful regulated promoters include the lac promoter (i.e., the lacZ promoter), particularly those in the family derived from the tac and trc promoters described in U.S. Patent No. 4,551,433, DeBoer, and Ptac16, Ptac17, PtacII, PlacUV5, and T7lac promoters. In one embodiment, the promoter is not derived from the host cell organism. In a specific embodiment, the promoter is derived from an E. coli organism.

[0034] Inducible promoter sequences are used to control crisantaspase expression according to the methods herein. In embodiments, inducible promoters useful in the methods herein include lac promoters (i.e., lacZ promoters), particularly those in the family derived from the tac and trc promoters described in U.S. Patent No. 4,551,433 to the DeBoer and Ptac16, Ptac17, PtacII, PlacUV5, and T7lac promoters. In one embodiment, the promoter is not native to the host cell organism. In a specific embodiment, the promoter is derived from an E. coli organism. In some embodiments, the lac promoter is used to control crisantaspase expression from a plasmid. In the case of a lac promoter derivative or family member, such as the tac promoter, the inducer is IPTG (isopropyl-β-D-1-thiogalactopyranoside, also known as "isopropylthiogalactoside"). In a specific embodiment, IPTG is added to the culture to induce crisantaspase expression from the lac promoter in a Pseudomonas host cell.

[0035] Common examples of non-lac-type promoters useful in expression systems according to the methods herein include, for example, those listed in Table 1.

[0036] [Table 1]

[0037] See, e.g., J. Sanchez-Romero & V. De Lorenzo, 1999, Manual of Industrial Microbiology and Biotechnology (A. Demain & J. Davies, eds.), pp. 460-74 (ASM Press, Washington, DC); H. Schweizer, 2001, Current Opinion in Biotechnology, 12:439-445; R. Slater & R. Williams, 2000, Molecular Biology and Biotechnology (J. Walker & R. Rapley, eds.), pp. 125-54 (The Royal Society of Chemistry, Cambridge, UK); and L.-M. Guzman, et al., 1995, J. Bacteriol. 177(14): 4121-4130, all of which are incorporated herein by reference. A promoter native to the selected bacterial host cell, e.g., a promoter having the nucleotide sequence of the Pseudomonas anthranilate or benzoate operon promoter (Pant, Pben), may be used to control expression of the transgene encoding the target polypeptide. Tandem promoters in which more than one promoter is covalently linked to another, whether within the same or different sequences and from the same or different organisms, may also be used, e.g., the Pant-Pben tandem promoter (inter-promoter hybrid) or the Plac-Plac tandem promoter.

[0038] A regulated promoter utilizes a promoter-regulatory protein to control the transcription of the gene of which the promoter is a part. When a regulated promoter is used herein, the corresponding promoter-regulatory protein will also be part of the expression system according to the methods herein. Examples of promoter-regulatory proteins include: activator proteins, such as the E. coli catabolite activator protein, MalT protein; AraC family transcription activators; repressor proteins, such as the E. coli LacI protein; and dual-function regulatory proteins, such as the E. coli NagC protein. Many regulated-promoter / promoter-regulatory protein pairs are known in the art. In one embodiment, the expression constructs for the target protein of interest and the heterologous protein are under the control of the same regulatory element.

[0039] The promoter-regulating protein interacts with an effector compound, i.e., a compound that reversibly or irreversibly interacts with the regulatory protein, allowing the protein to release or bind to at least one DNA transcriptional regulatory region of the gene under the promoter's control, thereby allowing or blocking the action of the transtranscriptase enzyme in initiating transcription of the gene. Effector compounds are classified as either inducers or corepressors, and these compounds include native effector compounds and gratuitous inducer compounds. Many regulated promoter / promoter-regulatory protein / effector compound trios are known in the art. In some cases, effector compounds are used throughout cell culture or fermentation, but in one embodiment where a regulated promoter is used, after growth of the host cell biomass to a desired amount or density, a suitable effector compound is added to the culture, directly or indirectly resulting in the expression of the desired gene encoding the protein or polypeptide of interest.

[0040] In embodiments in which a lac family promoter is utilized, the lacI gene is sometimes present in the system. The lacI gene, which is usually a constitutively expressed gene, encodes the LacI protein, a Lac repressor protein that binds to the lac operator of a Lac family promoter. Therefore, when a lac family promoter is utilized, the lacI gene is sometimes also included and expressed in the expression system.

[0041] Promoter systems useful in Pseudomonas are described in the literature, for example, in US Patent Application Publication No. 2008 / 0269070, also referenced above.

[0042] Other regulatory elements In embodiments, the soluble recombinant crisantaspase is present in either the cytoplasm or periplasm of the cell during production. Secretory leaders useful for targeting proteins, such as crisantaspase, are described elsewhere herein and in the above-referenced U.S. Patent Application Publication No. 2008 / 0193974, U.S. Patent Application Publication No. 2006 / 0008877, and U.S. Patent Application Ser. No. 12 / 610,207. In some embodiments, an expression construct is provided that encodes crisantaspase fused to a secretory leader that transports crisantaspase to the periplasm of Pseudomonad or Pseudomonas cells. In some embodiments, the secretory leader is cleaved from the crisantaspase protein. In some embodiments, the secretory leader facilitates production of soluble crisantaspase.

[0043] In embodiments, the expression vector contains an optimal ribosome binding sequence. Adjusting the translation strength by modifying the translation initiation region of the protein of interest can be used to improve the production of heterologous cytoplasm that accumulates primarily as inclusion bodies due to too fast a translation rate. Secretion of heterologous proteins into the periplasmic space of bacterial cells can also be enhanced by optimizing, rather than maximizing, the protein translation level so that the translation rate is synchronized with the protein secretion rate.

[0044] The translation initiation region has been defined as the sequence extending from immediately upstream of the ribosome binding site (RBS) to approximately 20 nucleotides downstream of the start codon (McCarthy et al. (1990) Trends in Genetics 6:78-85, incorporated herein by reference in its entirety). In prokaryotes, alternative RBS sequences can be utilized to optimize the translation level of a heterologous protein by providing a reduced translation rate relative to the translation level using the canonical, or consensus, RBS sequence (AGGAGG; SEQ ID NO: 50) described by Shine and Dalgarno (Proc. Natl. Acad. Sci. USA 71:1342-1346, 1974). By "translation rate" or "translation efficiency" is intended the rate at which mRNA is translated into protein within a cell. In most prokaryotes, the Shine-Dalgarno sequence assists in the binding and positioning of 30S ribosomal components relative to the start codon on mRNA through interactions with the pyrimidine-rich region of the 16S ribosomal RNA. The RBS (also referred to herein as the Shine-Dalgarno sequence) is located on the mRNA downstream from the start of transcription and upstream from the start of translation, typically 4 to 14 nucleotides upstream of the start codon, more typically 8 to 10 nucleotides upstream of the start codon. Because of the role of the RBS sequence in translation, there is a direct relationship between the efficiency of translation and the efficiency (or strength) of the RBS sequence.

[0045] In some embodiments, modification of the RBS sequence results in a decrease in the translation rate of the heterologous protein. This decrease in translation rate may correspond to an increase in the level of properly processed protein or polypeptide per gram of protein produced or per gram of host protein. A decreased translation rate can also correlate with an increased level of recoverable protein or polypeptide produced per gram of recombinant or per gram of host cell protein. A decreased translation rate can also correspond to any combination of increased expression, increased activity, increased solubility, or increased translocation (e.g., secretion into the periplasmic compartment or extracellular space). In this embodiment, the term "increased" refers to the level of produced, properly processed, soluble, and / or recoverable protein or polypeptide when the protein or polypeptide of interest is expressed under the same or substantially the same conditions, where the nucleotide sequence encoding the polypeptide contains a canonical RBS sequence. Similarly, the term "decreased" refers to the translation rate of a protein or polypeptide of interest when the gene encoding the protein or polypeptide contains a canonical RBS sequence. The translation rate can be reduced by at least about 5%, at least about 10%, at least about 15%, at least about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, at least about 75% or more, or by at least about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold or more.

[0046] In some embodiments, the RBS sequence variants described herein can be classified as resulting in high, medium, or low translation efficiency. In one embodiment, the sequences are ranked according to their level of translation activity compared to the translation activity of the canonical RBS sequence. High RBS sequences have about 60% to about 100% of the activity of the canonical sequence. Medium RBS sequences have about 40% to about 60% of the activity of the canonical sequence. Low RBS sequences have less than about 40% of the activity of the canonical sequence.

[0047] Examples of RBS sequences are shown in Table 2. Sequences were screened for translation strength using COP-GFP as a reporter gene and ranked according to the percentage of consensus RBS fluorescence. Each RBS variant was placed into one of three general fluorescence ranks: high ("Hi" - 100% consensus RBS fluorescence), medium ("Med" - 46-51% of consensus RBS fluorescence), and low ("Lo" - 16-29% consensus RBS fluorescence). [Table 2]

[0048] Expression constructs useful in practicing the methods herein include, in addition to the protein-coding sequence, the following regulatory elements operably linked thereto: a promoter, a ribosome binding site (RBS), a transcription terminator, and translation start and stop signals. Useful RBSs can be obtained from any species useful as a host cell in an expression system, e.g., according to U.S. Patent Application Publication No. 2008 / 0269070 and U.S. Patent Application Ser. No. 12 / 610,207. Many specific and diverse consensus RBSs are known, e.g., those described and referenced in D. Frishman et al., Gene 234(2):257-65 (8 Jul. 1999); and B.E. Suzek et al., Bioinformatics 17(12):1123-30 (December 2001). Additionally, either native or synthetic RBSs may be used, such as those described in EP 0207459 (synthetic RBSs); O. Ikehata et al., Eur. J. Biochem. 181(3):563-70 (1989). Further, examples of methods, parameters, and translation and transcription elements, and other elements useful in the methods herein, are described, for example, in U.S. Patent No. 5,055,294 to Gilroy and U.S. Patent No. 5,128,130 to Gilroy et al.; U.S. Patent No. 5,281,532 to Rammler et al.; U.S. Patent Nos. 4,695,455 and 4,861,595 to Barnes et al.; U.S. Patent No. 4,755,465 to Gray et al.; and U.S. Patent No. 5,169,760 to Wilcox.

[0049] Host strain Bacterial hosts, including Pseudomonads, and closely related bacterial organisms, are contemplated for use in the practice of the methods herein. In certain embodiments, the Pseudomonad host cell is Pseudomonas fluorescens. In some cases, the host cell is an E. coli cell.

[0050] Host cells and constructs useful in practicing the methods herein can be identified or generated using reagents and methods known in the art and are described in the literature, e.g., U.S. Patent Application Publication No. 2009 / 0325230, "Protein Expression Systems," incorporated herein by reference in its entirety. This publication describes the production of a recombinant polypeptide by introducing a nucleic acid construct into an auxotrophic Pseudomonas fluorescens host cell containing a chromosomal lacI gene insert. The nucleic acid construct comprises a nucleotide sequence encoding a recombinant polypeptide operably linked to a promoter capable of directing expression of the nucleic acid in the host cell, and also comprises a nucleotide sequence encoding an auxotrophic selectable marker. The auxotrophic selectable marker is a polypeptide that restores prototrophy to the auxotrophic host cell. In embodiments, the cells are auxotrophic for proline, uracil, or a combination thereof. In embodiments, the host cell is derived from MB101 (ATCC deposit PTA-7841). U.S. Patent Application Publication No. 2009 / 0325230, "Protein Expression Systems," and Schneider, et al., 2005, "Auxotrophic markers pyrF and proC, in some cases, replace antibiotic markers on protein production plasmids in high-cell-density Pseudomonas fluorescens fermentation," Biotechnol. Progress 21(2):343-8, both of which are incorporated herein by reference in their entireties, describe a production host strain auxotrophic for uracil constructed by deleting the pyrF gene in strain MB101. The pyrF gene was cloned from strain MB214 (ATCC deposit PTA-7840) to generate a plasmid that complements the pyrF deletion and restores prototrophy. In certain embodiments, a dual pyrF-proC dual auxotrophic selection marker system in P. fluorescens host cells is used.The described pyrF deletion production host strain is often used as a background for introducing other desired genomic changes, including those described herein as useful in the practice of the methods herein.

[0051] In embodiments, host cells useful in the methods of the present invention are deficient in expression of at least one protease, overexpress at least one folding modulator, or both. In embodiments, the host cells are not deficient in expression of a protease or overexpress a folding modulator, and are therefore wild-type with respect to protease and folding modulator expression. In any of these embodiments, the host cells are additionally deficient in native L-asparaginase. In embodiments, the deficiency in native L-asparaginase is generated by deleting or otherwise inactivating the native L-asparaginase gene using any suitable method known in the art. In embodiments, the host cells are deficient in native type I L-asparaginase, native type II L-asparaginase, or both. In embodiments, the host cells are wild-type with respect to protease and folding modulator expression and deficient in native type I L-asparaginase and native type II L-asparaginase. For example, host cells useful in the methods of the present invention can be generated by one of skill in the art from MB101 using known methods. In embodiments, the host cells are generated by deleting or otherwise inactivating the native type I L-asparaginase gene, the native type II L-asparaginase gene, or both, in MB101.

[0052] Those skilled in the art will understand that production host strains useful in the methods of the present invention can be generated using publicly available host cells, such as P. fluorescens MB101, by inactivating the pyrF gene and / or the native type I L-asparaginase gene and / or the native type II L-asparaginase gene, using any of a number of suitable methods known in the art and described in the literature. It will also be understood that a prototrophy-restoring plasmid can be transformed into a plasmid carrying the pyrF gene from a strain, such as strain MB214, using any of a number of suitable methods known in the art and described in the literature. Additionally, in such strains, proteases can be inactivated and folding modulator overexpression constructs can be introduced using methods well known in the art.

[0053] In an embodiment, the host cell is of the order Pseudomonadales. When the host cell is of the order Pseudomonadales, it may be a member of the family Pseudomonadaceae, which includes the genus Pseudomonas. Gammaproteobacterial hosts include members of the species Escherichia coli and Pseudomonas fluorescens. Host cells of the order Pseudomonadales, family Pseudomonadaceae, or genus Pseudomonas can be identified by those skilled in the art and are described in the literature (e.g., Bergey's Manual of Systematics of Archaea and Bacteria (online publication, 2015)). Other Pseudomonas organisms may also be useful. Pseudomonads and closely related species include the Gram-negative Proteobacteria subgroup 1, which includes groups of Proteobacteria belonging to families and / or genera listed in Bergey's Manual of Systematics of Archaea and Bacteria (published online, 2015). Table 3 lists these families and genera of organisms. [Table 3]

[0054] Pseudomonas and closely related bacteria are part of the group commonly defined as "Gram(-) Proteobacteria subgroup 1" or "Gram-negative aerobic bacilli and cocci" (Bergey's Manual of Systematics of Archaea and Bacteria, published online, 2015). Pseudomonas host strains are described in the literature, for example, in the above-cited U.S. Patent Application Publication No. 2006 / 0040352.

[0055] "Gram-negative Proteobacteria subgroup 1" also includes Proteobacteria that would be classified under this heading according to the criteria used in classification. The heading also includes groups previously classified under this section but no longer classified, such as the genera Acidovorax, Brevundimonas, Burkholderia, Hydrogenophaga, Oceanimonas, Ralstonia, and Stenotrophomonas, the genus Sphingomonas (and the genus BLASTomonas derived from it) resulting from regrouping organisms within the genus Xanthomonas, and the genus Acidomonas resulting from regrouping organisms within the family Acetobacterium as defined in Bergey's Manual of Systematics of Archaea and Bacteria (published online, 2015). Additionally, hosts include cells from the genera Pseudomonas, Pseudomonas enalia (ATCC 14393), Pseudomonas nigrifaciensi (ATCC 19375), and Pseudomonas putrefaciens (ATCC 8071), classified as Alteromonas haloplankti, Alteromonas nigrifaciens, and Alteromonas putrefaciens, respectively. Similarly, for example, Pseudomonas acidovorans (ATCC 15668) and Pseudomonas testosteroni (ATCC 11996) have been reclassified as Comamonas acidovorans and Comamonas testosteroni, respectively; Pseudomonas nigrifaciens (ATCC 19375) and Pseudomonas piscicida (ATCC 15057) have been reclassified as Pseudoalteromonas nigrifaciens and Pseudoalteromonas piscicida, respectively."Gram-negative Proteobacteria Subgroup 1" also includes Proteobacteria classified as belonging to any of the families: Pseudomonadaceae, Azotobacteraceae (now often synonymized as the "Azotobacter group" of Pseudomonadaceae), Rhizobiacea, and Methylomonadaceae (now often synonymized as "Methylococcaceae"). As a result, in addition to the genera otherwise described herein, the genus Proteobacteria 1 included in "Gram-negative Proteobacteria subgenus 1" further includes: 1) Azotobacter group bacteria of the genus Azorhizophilus; 2) Pseudomonadaceae family bacteria of the genera Vibrio, Oligella, and Teredinibacter; 3) Rhizobiaceae family bacteria of the genera Chelatobacter, Ensifer, Liberibacter (also known as "Candidatus Liberibacter"), and Sinorhizobium; and 4) Methylococcaceae family bacteria of the genera Methylobacter, Methylocaldum, Methylomicrobium, Methylosarcina, and Methylosphaera.

[0056] In some cases, the host cell is selected from "Gram-negative Proteobacteria subgroup 16." "Gram-negative Proteobacteria Subgroup 16" is defined as the group of proteobacteria of the following Pseudomonas species (with ATCC or other deposit numbers of exemplary strains shown in parentheses): Pseudomonas abietaniphila (ATCC 700689); Pseudomonas aeruginosa (ATCC 10145); Pseudomonas alcaligenes (ATCC 14909); Pseudomonas anguilliseptica (ATCC 33660); Pseudomonas citronellolis (ATCC 13674); Pseudomonas flavescens (ATCC 51555); Pseudomonas mendocina (ATCC 25411); Pseudomonas nitroreducens (ATCC 33634); Pseudomonas oleovorans (ATCC 8062); Pseudomonas pseudoalcaligenes (ATCC Pseudomonas straminea (ATCC 33636); Pseudomonas agarici (ATCC 25941); Pseudomonas alcaliphila; Pseudomonas alginovora; Pseudomonas andersonii; Pseudomonas asplenii (ATCC 23835); Pseudomonas azelaica (ATCC 27162); Pseudomonas beyerinckii (ATCC 19372); Pseudomonas borealis; Pseudomonas boreopolis (ATCC 33662); Pseudomonas brassicacearum; Pseudomonas butanovora (ATCC 43655); Pseudomonas cellulosa (ATCC 55703);Pseudomonas aurantiaca (ATCC 33663); Pseudomonas chlororaphis (ATCC 9446, ATCC 13985, ATCC 17418, ATCC 17461); Pseudomonas fragi (ATCC 4973); Pseudomonas lundensis (ATCC 49968); Pseudomonas taetrolens (ATCC 4683); Pseudomonas cissicola (ATCC 33616); Pseudomonas coronafaciens; Pseudomonas diterpeniphila; Pseudomonas elongata (ATCC 10144); Pseudomonas flectens (ATCC 12775); Pseudomonas azotoformans; Pseudomonas brenneri; Pseudomonas cedrella; Pseudomonas corrugata (ATCC 29736); Pseudomonas extremorientalis; Pseudomonas fluorescens (ATCC 35858); Pseudomonas gessardii; Pseudomonas libanensis; Pseudomonas mandelii (ATCC 700871); Pseudomonas marginalis (ATCC 10844); Pseudomonas migulae; Pseudomonas mucidolens (ATCC 4685); Pseudomonas orientalis; Pseudomonas rhodesiae; Pseudomonas synxantha (ATCC 9890); Pseudomonas tolaasii (ATCC 33618); Pseudomonas veronii (ATCC 700474); Pseudomonas frederiksbergensis; Pseudomonas geniculata (ATCC 19374); Pseudomonas gingeri; Pseudomonas graminis;Pseudomonas grimontii; Pseudomonas halodenitrificans; Pseudomonas halophila; Pseudomonas hibiscicola (ATCC 19867); Pseudomonas huttiensis (ATCC 14670); Pseudomonas hydrogenovora; Pseudomonas jessenii (ATCC 700870); Pseudomonas kilonensis; Pseudomonas lanceolata (ATCC 14669); Pseudomonas lini; Pseudomonas marginata (ATCC 25417); Pseudomonas mephitica (ATCC 33665); Pseudomonas denitrificans (ATCC 19244); Pseudomonas pertucinogena (ATCC 190); Pseudomonas pictorum (ATCC 23328); Pseudomonas psychrophila; Pseudomonas filva (ATCC 31418); Pseudomonas monteilii (ATCC 700476); Pseudomonas mosselii; Pseudomonas oryzihabitans (ATCC 43272); Pseudomonas plecoglossicida (ATCC 700383); Pseudomonas putida (ATCC 12633); Pseudomonas reactans; Pseudomonas spinosa (ATCC 14606); Pseudomonas balearica; Pseudomonas luteola (ATCC 43273);. Pseudomonas stutzeri (ATCC 17588); Pseudomonas amygdali (ATCC 33614); Pseudomonas avellanae (ATCC 700331); Pseudomonas caricapapayae (ATCC 33615);Pseudomonas cichorii (ATCC 10857); Pseudomonas ficuserectae (ATCC 35104); Pseudomonas fuscovaginae; Pseudomonas meliae (ATCC 33050); Pseudomonas syringae (ATCC 19310); Pseudomonas viridiflava (ATCC 13223); Pseudomonas thermocarboxydovorans (ATCC 35961); Pseudomonas thermotolerans; Pseudomonas thivervalensis; Pseudomonas vancouverensis (ATCC 700688); Pseudomonas wisconsinensis; and Pseudomonas xiamenensis. In one embodiment, the host cell for expression of crisantaspase is Pseudomonas fluorescens.

[0057] In some cases, the host cell is selected from "Gram-negative Proteobacteria subgroup 17." "Gram-negative Proteobacteria Subgroup 17" is defined as the group of Proteobacteria known in the art as "fluorescent Pseudomonads" that includes, for example, members of the following Pseudomonas species: Pseudomonas azotoformans; Pseudomonas brenneri; Pseudomonas cedrella; Pseudomonas cedrina; Pseudomonas corrugata; Pseudomonas extremorientalis; Pseudomonas fluorescens; Pseudomonas gessardii; Pseudomonas libanensis; Pseudomonas mandelii; Pseudomonas marginalis; Pseudomonas migulae; Pseudomonas mucidolens; Pseudomonas orientalis; Pseudomonas rhodesiae; Pseudomonas synxantha; Pseudomonas tolaasii; and Pseudomonas veronii.

[0058] Proteases In one embodiment, the methods provided herein involve producing a recombinant crisantaspase protein using a Pseudomonas host cell containing one or more mutations (e.g., partial or complete deletions) in one or more protease genes. In some embodiments, the mutations in the protease genes facilitate production of the recombinant crisantaspase protein.

[0059] Exemplary target protease genes include those proteases classified as follows: aminopeptidases; dipeptidases; dipeptidyl and tripeptidyl peptidases; peptidyl dipeptidases; serine-type carboxypeptidases; metallocarboxypeptidases; cysteine-type carboxypeptidases; omega peptidases; serine proteinases; cysteine ​​proteinases; aspartic acid proteinases; metalloproteinases; or proteinases of unknown mechanism.

[0060] Aminopeptidases include cytosolic aminopeptidase (leucyl aminopeptidase), membrane alanyl aminopeptidase, cystinyl aminopeptidase, tripeptide aminopeptidase, prolyl aminopeptidase, arginyl aminopeptidase, glutamyl aminopeptidase, x-pro aminopeptidase, bacterial leucyl aminopeptidase, thermophilic aminopeptidase, clostridial aminopeptidase, cytosolic alanyl aminopeptidase, lysyl aminopeptidase, x-trp aminopeptidase, tryptophanyl aminopeptidase, methionyl aminopeptidase, d-stereospecific aminopeptidase, and aminopeptidase EY. Dipeptidases include x-his dipeptidase, x-arg dipeptidase, x-methyl-his dipeptidase, cys-gly dipeptidase, glu-glu dipeptidase, pro-x dipeptidase, x-pro dipeptidase, met-x dipeptidase, non-stereospecific dipeptidase, cytosolic non-specific dipeptidase, membrane dipeptidase, and beta-ala-his dipeptidase. Dipeptidyl peptidases and tripeptidyl peptidases include dipeptidyl peptidase I, dipeptidyl peptidase II, dipeptidyl peptidase III, dipeptidyl peptidase IV, dipeptidyl dipeptidase, tripeptidyl peptidase I, and tripeptidyl peptidase II. Peptidyl dipeptidases include peptidyl dipeptidase A and peptidyl dipeptidase B. Serine carboxypeptidases include lysosomal pro-x carboxypeptidase, serine D-ala-D-ala carboxypeptidase, carboxypeptidase C, and carboxypeptidase D.Metallocarboxypeptidases include carboxypeptidase a, carboxypeptidase B, lysine (arginine) carboxypeptidase, gly-X carboxypeptidase, alanine carboxypeptidase, muramoyl pentapeptide carboxypeptidase, carboxypeptidase h, glutamate carboxypeptidase, carboxypeptidase M, muramoyl tetrapeptide carboxypeptidase, zinc d-ala-d-ala carboxypeptidase, carboxypeptidase A2, membrane pro-x carboxypeptidase, tubulinyl-tyr carboxypeptidase, and carboxypeptidase t. Omega peptidases include acylaminoacyl-peptidase, peptidyl-glycine amidase, pyroglutamyl-peptidase I, beta-aspartyl-peptidase, pyroglutamyl-peptidase II, n-formylmethionyl-peptidase, pteroylpoly-[gamma]-glutamate carboxypeptidase, gamma-glu-X carboxypeptidase, and acylmuramoyl-ala peptidase.Serine proteinases include chymotrypsin, chymotrypsin c, metlidin, trypsin, thrombin, coagulation factor Xa, plasmin, enteropeptidase, acrosin, alpha-lytic protease, glutamyl endopeptidase, cathepsin G, coagulation factor viia, coagulation factor ixa, cucumis, prolyl oligopeptidase, coagulation factor xia, brachyurin, plasma kallikrein, and tissue kallikrein. Recreain, pancreatic elastase, leukocyte elastase, coagulation factor xiia, chymase, complement component c1r55, complement component c1s55, classical complement pathway c3 / c5 convertase, complement factor I, complement factor D, alternative complement pathway c3 / c5 convertase, cerevisiae, hypodermin C, lysyl endopeptidase, endopeptidase 1a, gamma-ren, benovin ab, leucyl endopeptidase, tryptase, These include scutellarin, kexin, subtilisin, oryzin, endopeptidase k, thermomycolin, thermitase, endopeptidase SO, T-plasminogen activator, protein C, pancreatic endopeptidase E, pancreatic elastase II, IGA-specific serine endopeptidase, U-plasminogen activator, benovin A, furin, myeloblastin, semenogelase, granzyme A or cytotoxic T-lymphocyte proteinase 1, granzyme B or cytotoxic T-lymphocyte proteinase 2, streptoglycin A, streptoglycin B, glutamyl endopeptidase II, oligopeptidase B, limulus clotting factor c, limulus clotting factor, limulus clotting enzyme, omputin, repressor lexa, bacterial leader peptidase I, togavirin, and flavrin. Cysteine ​​proteinases include cathepsin B, papain, ficin, chymopapain, asclepain, clostripain, streptopain, actinides, cathepsin 1, cathepsin H, calpain, cathepsin T, glycylendopeptidase, cancer procoagulant, cathepsin S, picornain 3C, picornain 2A, caricain, ananain, stem bromelain, fruit bromelain, legumain, histricein, and interleukin-1 beta converting enzyme.Aspartic proteinases include pepsin A, pepsin B, gastricsin, chymosin, cathepsin D, neopentesin, renin, retropepsin, pro-opiomelanocortin convertase, aspergillopepsin I, aspergillopepsin II, penicillopepsin, rhizopuspepsin, endothiapepsin, mucolopepsin, candidapepsin, saccharopepsin, rhodotorulapepsin, physalopepsin, acrocylindropepsin, polypolopepsin, pycnopolopepsin, scitalidopepsin a, scitalidopepsin b, xanthomonapepsin, cathepsin e, bariapepsin, bacterial leader peptidase I, pseudomonapepsin, and plasmepsin. Metalloproteinases include atrorlysin A, microbial collagenase, leucolisin, interstitial collagenase, neprilysin, envelysin, IgA-specific metalloendopeptidase, procollagen N-endopeptidase, thimeto-oligopeptidase, neurolysin, stromelysin 1, meprin A, procollagen C-endopeptidase, peptidyl-lys metalloendopeptidase, astacin, stromelysin 2, matrilysin gelatinase, aeromonolysin, pseudolysin, thermolysin, bacillolysin, aureolysin, coccolysin, mycolysin, beta-lytic metalloendopeptidase, peptidyl-asp metalloendopeptidase Proteinases of unknown mechanism include thermopsin and the multicatalytic endopeptidase complex.

[0061] Certain proteases have both protease and chaperone-like activities. When these proteases negatively affect protein yield and / or quality, it is often useful to specifically delete their protease activity, whereas when their chaperone activity may positively affect protein yield and / or quality, they are overexpressed. These proteases include Hsp100 (Clp / Hsl) family members RXF04587.1 (clpA), RXF08347.1, RXF04654.2 (clpX), RXF04663.1, RXF01957.2 (hslU), and RXF01961.2 (hslV); peptidyl-prolyl cis-trans isomerase family member RXF05345.2 (ppiB); and metallopeptidases. These include, but are not limited to, the M20 family member RXF04892.1 (aminohydrolase); the metallopeptidase M24 family members RXF04693.1 (methionine aminopeptidase) and RXF03364.1 (methionine aminopeptidase); and the serine peptidase S26 signal peptidase I family member RXF01181.1 (signal peptidase).

[0062] In embodiments, host strains useful for expressing crisantaspase in the methods of the invention are Pseudomonas host strains, e.g., P. fluorescens, that have protease deficiencies or inactivations (e.g., resulting from deletions, partial deletions, or knockouts) and / or overexpress folding modulators, e.g., from a plasmid or bacterial chromosome. In embodiments, the host strain is deficient in at least one protease selected from Lon, HslUV, DegP1, DegP2, Prc, AprA, DegP2 S219A, Prc1, and AprA. In embodiments, the host strain overexpresses a folding modulator selected from LepB, Tig, and DsbAC-Skp (i.e., a combination of DsbA, DsbC, and Skp; Skp is OmpHRXF4702.1, set forth herein as SEQ ID NO:59, with an example coding sequence set forth herein as SEQ ID NO:60). In a DsbAC-Skp overexpressor host, the folding modulators DsbA, DsbC, and Skp (SEQ ID NOS:25 and 26 in U.S. Patent No. 9,394,571 and SEQ ID NO:60 herein, respectively) can be expressed from an operon. In embodiments, the host strain is deficient in at least one protease selected from Lon, HslUV, DegP1, DegP2, Prc, AprA, DegP2 S219A, Prc1, and AprA, and overexpresses at least one folding modulator selected from LepB, Tig, and DsbAC-Skp. In any of the above embodiments, the host strain expresses the auxotrophic markers pyrF and proC, has a protease deficiency, and / or overexpresses a folding modulator. In embodiments, the host strain expresses any other suitable selectable marker known in the art. In any of the above embodiments, the asparaginase, eg, native type I and / or type II asparaginase, is inactivated in the host strain.In embodiments, the host strain is a Pseudomonadales host cell that is: deficient in Lon and HslU / V; deficient in Lon, DegP1, DegP2, Prc, and AprA; Host cells deficient in S219A, Prc1, and AprA and overexpressing DsbAC-Skp; deficient in AspG1 and / or AspG2; deficient in AspG1 and / or AspG2 and overexpressing Tig; deficient in AspG1 and / or AspG2 and overexpressing LepB; deficient in AspG1 and / or AspG2 and deficient in Lon and HslU / V; deficient in AspG1 and / or AspG2 and deficient in Lon, DegP1, DegP2, Prc, and AprA; or host cells deficient in AspG1 and / or AspG2, Lon, DegP1, DegP2, Prc1, and AprA and overexpressing DsbAC-Skp.

[0063] These and other proteases and folding modulators are known in the art and are described in the literature, e.g., U.S. Patent No. 8,603,824. For example, Table D of the patent describes Tig (tig, trigger factor, FKBP-type ppiase (ec 5.2.1.8) RXF04655, UniProtKB-P0A850 (TIG_E.COLI)). "Method for Rapidly Screening Microbial Hosts to Identify Certain Strains with Improved Yield and / or Quality in the Expression of Heterologous WO 2008 / 134461 and U.S. Patent No. 9,394,571, entitled "Proteins," which are incorporated by reference herein in their entireties, describe Tig (RXF04655.2, therein SEQ ID NO: 34), LepB (RXF01181.1, therein SEQ ID NO: 56), DegP1 (RXF01250, therein SEQ ID NO: 57), AprA (RXF04304.1, therein SEQ ID NO: 86), Prc1 (RXF06586.1, therein SEQ ID NO: 120), DegP2, (RXF07210.1, therein SEQ ID NO: 124), Lon (RXF04653, therein SEQ ID NO: 92); DsbA (RXF01002.1, therein SEQ ID NO: 25), and DsbC (RXF03307.1, therein SEQ ID NO: 26). These sequences and those of other protease and folding modulators are also described in U.S. Patent No. 9,580,719 (the table of SEQ ID NOs: 93-98 therein). For example, U.S. Patent No. 9,580,719 provides sequences encoding HslU (RXF01957.2) and HslV (RXF01961.2) as SEQ ID NOs: 18 and 19, respectively.

[0064] Codon optimization In one embodiment, the method herein involves expression of recombinant crisantaspase from a construct optimized for codon usage in a strain of interest. In an embodiment, the strain is a Pseudomonas host cell, e.g., Pseudomonas fluorescens. Methods for optimizing codons to improve expression in bacterial hosts are known in the art and described in the literature. For example, codon optimization for expression in Pseudomonas host strains is described in U.S. Patent Application Publication No. 2007 / 0292918, "Codon Optimization Method," which is incorporated herein by reference in its entirety.

[0065] In heterologous expression systems, optimization may improve the host's ability to produce foreign proteins. Protein expression is governed by a host of factors, including those affecting transcription, mRNA processing, and translation stability and initiation. Polynucleotide optimization may include improving the host's ability to produce foreign proteins and assisting researchers in efficiently designing expression constructs. Optimization strategies may include, for example, modifying the translation initiation region, altering mRNA structural elements, and using different codon biases. Methods for optimizing nucleic acid sequences to improve heterologous protein expression in bacterial hosts are known in the art and described in the literature. For example, codon optimization for expression in Pseudomonas host strains is described, for example, in U.S. Patent Application Publication No. 2007 / 0292918, "Codon Optimization Method," incorporated herein by reference in its entirety.

[0066] Optimization addresses any of a number of sequence characteristics of heterologous genes. As a specific example, rare codon-induced translational pausing often results in reduced heterologous protein expression. Rare codon-induced translational pausing includes the presence of codons in the target polynucleotide that are rarely used in the host organism and may have a negative effect on protein translation due to lack of available tRNA pools. One method for improving optimal translation in a host organism involves performing codon optimization, which sometimes results in rare host codons being removed from the synthetic polynucleotide sequence.

[0067] Alternate translation initiation also sometimes results in reduced, non-identical protein expression. Alternate translation initiation includes synthetic polynucleotide sequences that erroneously contain motifs that can function as ribosome binding sites (RBS). In some cases, these sites result in the initiation of translation of truncated proteins from internal gene sites. One method to reduce the likelihood of producing truncated proteins, which are often difficult to remove during purification, involves eliminating predicted internal RBS sequences from the optimized polynucleotide sequence.

[0068] Repeat-induced polymerase slippage often results in reduced heterologous protein expression. Repeat-induced polymerase slippage includes nucleotide sequence repeats that have been shown to cause DNA polymerase slippage or disruption, sometimes resulting in frameshift mutations. Such repeats also often cause RNA polymerase slippage. In organisms with a high G+C content bias, there are sometimes higher degrees of repeats composed of G or C nucleotide repeats. Therefore, one way to reduce the likelihood of inducing RNA polymerase slippage involves modifying the extended repeats of G or C nucleotides.

[0069] Interference with secondary structure also sometimes results in reduced heterologous protein expression. Secondary structure often isolates the RBS sequence or start codon and is correlated with reduced protein expression. Stem-loop structures are also often involved in transcription pausing and attenuation. Optimized polynucleotide sequences usually contain minimal secondary structure within the RBS and gene-coding regions of the nucleotide sequence, allowing for improved transcription and translation.

[0070] Another feature that sometimes affects heterologous protein expression is the presence of restriction sites. Polynucleotide sequences are optimized by removing restriction sites that would interfere with subsequent subcloning of the transcription unit into a host expression vector.

[0071] For example, the optimization process often begins by identifying a desired amino acid sequence that will be heterologously expressed by a host. Candidate polynucleotides or DNAs are designed from the amino acid sequence. During the design of a synthetic DNA sequence, codon usage is compared with the codon usage of the host expression organism, and rare host codons are removed from the synthetic sequence. In addition, the synthetic candidate DNA sequence is sometimes modified to remove undesired enzyme restriction sites and to add or remove any desired signal sequences, linkers, or untranslated regions. Synthetic DNA sequences are often analyzed for the presence of secondary structures that may interfere with the translation process, such as G / C repeats and stem-loop structures. Prior to synthesizing the candidate DNA sequence, the optimized sequence design is often checked to ensure that the sequence correctly encodes the desired amino acid sequence. Finally, the candidate DNA sequence is synthesized using DNA synthesis techniques, such as those known in the art.

[0072] In another embodiment of the present disclosure, common codon usage in a host organism, such as P. fluorescens, is often utilized to optimize expression of heterologous polynucleotide sequences. The percentage and distribution of codons rarely considered preferred for a particular amino acid in the host expression system are evaluated. Values ​​of 5% and 10% usage are often used as cutoff values ​​for determining rare codons. For example, the codons listed in Table 4 have a calculated occurrence of less than 5% in the P. fluorescens MB214 genome and are generally avoided in optimized genes expressed in P. fluorescens hosts. [Table 4]

[0073] The present disclosure contemplates the use of any crisantaspase-encoding sequence, including any sequence optimized for expression in the Pseudomonas host cell being used. Sequences contemplated for use are often optimized to any degree desired, including, but not limited to, optimization to exclude the following: codons occurring less than 5% of the time in Pseudomonas host cells, codons occurring less than 10% of the time in Pseudomonas host cells, rare codon-induced translational pauses, putative internal RBS sequences, extended repeats of G or C nucleotides, interfering secondary structures, restriction sites, or combinations thereof.

[0074] Furthermore, the amino acid sequence of any secretory leader useful in the practice of the methods provided herein can be encoded by any suitable nucleic acid sequence. Codon optimization for expression in E. coli is described, for example, by Welch et al., 2009, PLoS One, "Design Parameters to Control Synthetic Gene Expression in Escherichia coli," 4(9): e7002; Ghane et al., 2008; and Krishna R. et al., (2008) Mol Biotechnology, "Optimization of the AT-content of Codons Immediately Downstream of the Initiation Codon and Evaluation of Culture Conditions for High-Level Expression of Recombinant Human G-CSF in Escherichia coli," 38:221-232.

[0075] High Throughput Screen In some embodiments, high-throughput screens are often performed to determine optimal conditions for expressing soluble recombinant crisantaspase. Conditions varied in the screen include, for example, the host cell, the genetic background of the host cell (e.g., deletion of different proteases), the type of promoter in the expression construct, the type of secretion leader fused to the encoded crisantaspase, the temperature of growth, the OD of induction when an inducible promoter is used, the amount of inducer added (e.g., the amount of IPTG used for induction when the lacZ promoter or its derivatives is used), the duration of protein induction, the temperature of growth following addition of the inducer to the culture, the agitation rate of the culture, the method of selection for plasmid maintenance, the volume of culture in the vessel, and the method of cell lysis.

[0076] In some embodiments, a library (or "array") of host strains is provided, where each strain (or "population of host cells") in the library has been genetically modified to regulate the expression of one or more target genes in the host cells. An "optimal host strain" or "optimal expression system" is often identified or selected based on the quantity, quality, and / or location of the expressed protein of interest relative to other populations of phenotypically distinct host cells in the array. Thus, an optimal host strain is one that produces a polypeptide of interest according to desired specifications. The desired specifications will vary depending on the polypeptide being produced, but specifications may include protein quality and / or quantity, whether the protein is sequestered (e.g., in inclusion bodies) or secreted, protein folding, etc. For example, an optimal host strain or optimal expression system will produce a yield characterized by the amount of soluble heterologous protein, the amount of recoverable heterologous protein, the amount of properly processed heterologous protein, the amount of properly folded non-identical protein, the amount of active non-identical protein, and / or a particular absolute level or a particular level of total heterologous protein relative to that produced by an indicator strain, i.e., a strain used for comparison.

[0077] Methods for screening microbial hosts to identify strains with improved yield and / or quality in heterologous protein expression are described, for example, in US Patent Application Publication No. 20080269070.

[0078] Bacterial growth status Growth conditions useful in the methods herein often include a temperature of about 4° C. to about 42° C. and a pH of about 5.7 to about 8.8. When an expression construct having the lacZ promoter or a derivative thereof is used, expression is often induced by adding IPTG to the culture at a final concentration of about 0.01 mM to about 1.0 mM.

[0079] The pH of the culture is often maintained using pH buffers and methods known to those skilled in the art. pH control during cultivation is often achieved using aqueous ammonia. In embodiments, the pH of the culture is about 5.7 to about 8.8. In certain embodiments, the pH is about 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, or 8.8. In other embodiments, the pH is about 5.7 to 5.9, 5.8 to 6.0, 5.9 to 6.1, 6.0 to 6.2, 6.1 to 6.3, 6.2 to 6.5, 6.4 to 6.7, 6.5 to 6.8, 6.6 to 6.9, 6.7 to 7.0, 6.8 to 7.1, 6.9 to 7.2, 7.0 to 7.3, 7.1 to 7.4, 7.2 to 7.5, 7.3 to 7.6, 7.4 to 7.7, 7.5 to 7.8, 7.6 to 7.9, 7.7 to 8.0, 7.8 to 8.1, 7.9 to 8.2, 8.0 to 8.3, 8.1 to 8.4, 8.2 to 8.5, 8.3 to 8.6, 8.4 to 8.7, or 8.5 to 8.8. In still other embodiments, the pH is about 5.7 to 6.0, 5.8 to 6.1, 5.9 to 6.2, 6.0 to 6.3, 6.1 to 6.4, or 6.2 to 6.5. In certain embodiments, the pH is about 5.7 to about 6.25. In some embodiments, the pH is about 5.0 to about 8.0.

[0080] In an embodiment, the growth temperature is maintained at about 4°C to about 42°C. In certain embodiments, the growth temperature is about 4°C, about 5°C, about 6°C, about 7°C, about 8°C, about 9°C, about 10°C, about 11°C, about 12°C, about 13°C, about 14°C, about 15°C, about 16°C, about 17°C, about 18°C, about 19°C, about 20°C, about 21°C, about 22°C, about 23°C, about 24°C, about 25°C, about 26°C, about 27°C, about 28°C, about 29°C, about 30°C, about 31°C, about 32°C, about 33°C, about 34°C, about 35°C, about 36°C, about 37°C, about 38°C, about 39°C, about 40°C, about 41°C, or about 42°C. In other embodiments, the growth temperature is from about 25°C to about 27°C, from about 25°C to about 28°C, from about 25°C to about 29°C, from about 25°C to about 30°C, from about 25°C to about 31°C, from about 25°C to about 32°C, from about 25°C to about 33°C, from about 26°C to about 28°C, from about 26°C to about 29°C, from about 26°C to about 30°C, from about 26°C to about 31°C, from about 26°C to about 32°C, from about 27°C to about 29°C, from about 27°C to about 30°C, from about 27°C to about 30°C, In embodiments, the growth temperature is maintained at about 22°C to about 33°C. In other embodiments, the temperature is varied during cultivation. In certain embodiments, the temperature is maintained at about 30° C. to about 32° C. before an agent that induces expression from a construct encoding a polypeptide or protein of interest is added to the culture, and after the addition of the agent that induces expression, e.g., IPTG, is added to the culture, the temperature is reduced to about 25° C. to about 27° C. In one embodiment, the temperature is maintained at about 30° C. before an agent that induces expression from a construct encoding a polypeptide or protein of interest is added to the culture, and after the addition of the agent that induces expression, the temperature is reduced to about 25° C.

[0081] Induction As described elsewhere herein, inducible promoters are often used in expression constructs to control expression of recombinant crisantaspase, e.g., the lac promoter. In the case of a lac promoter derivative or family member, e.g., the tac promoter, the effector compound is an inducer, such as a PTG-like gratuitous inducer (isopropyl-β-D-1-thiogalactopyranoside, also known as "isopropylthiogalactoside"). In embodiments, a lac promoter derivative is used, and crisantaspase expression is induced by the addition of IPTG to a final concentration of about 0.01 mM to about 1.0 mM when cell density reaches a level determined by an OD575 of about 25 to about 160. In embodiments, the OD575 upon induction of crisantaspase in the culture is about 25, about 50, about 55, about 60, about 65, about 70, about 80, about 90, about 100, about 110, about 120, about 130, about 140, about 150, about 160, about 170, or about 180. In other embodiments, the OD575 is about 80 to about 100, about 100 to about 120, about 120 to about 140, or about 140 to about 160. In other embodiments, the OD575 is about 80 to about 120, about 100 to about 140, or about 120 to about 160. In other embodiments, the OD575 is about 80 to about 140, or about 100 to 160. Cell density is often measured by other methods and expressed in other units, such as cells per unit volume. For example, an OD25 of about 25 to about 160 for a Pseudomonas fluorescens culture corresponds to approximately 2.5 x 10 per mL. 10 From about 1.6x10 11 or 11 to 70 g / L dry cell weight, or equivalent to about 0.05 g / g to about 0.4 g / g wet cell weight. In embodiments, the OD575 cell density measurement is 1 x 10 9an OD575 conversion of 1 equal to 0.002 g / g is converted to a measure of CFU; an OD575 conversion of 1 equal to 0.002 g / g is converted to a measure of wet cell weight; and an OD575 conversion of 1 equal to 0.44 g / L is converted to a measure of dry cell weight. In embodiments, crisantaspase expression is induced by the addition of IPTG to a final concentration of about 0.01 mM to about 1.0 mM when the cell density reaches about 0.05 g / g to about 0.4 g / g wet weight. In embodiments, the wet cell weight is about 0.05 g / g, about 0.1 g / g, about 0.15 g / g, about 0.2 g / g, about 0.25 g / g, about 0.30 g / g, about 0.35 g / g, about 0.40 g / g, about 0.05 g / g to about 0.1 g / g, about 0.05 g / g to about 0.15 g / g, about 0.05 g / g to about 0.20 g / g, about 0.05 g / g to about 0.25 g / g, about 0.05 g / g to about 0.30 g / g, about 0.05 g / g to about 0.35 g / g, about 0.1 g / g to about 0.40 g / g, about 0.15 g / g to about 0.40 g / g, about 0.20 g / g to about 0.40 g / g, about 0.25 g / g to about 0.40 g / g, about 0.30 g / g to about 0.40 g / g, or about 0.35 g / g to about 0.40 g / g. In embodiments, the wet cell weight is about 0.1 g / g to about 0.5 g / g. In embodiments, the cell density at the time of induction of the culture is equivalent to the cell density specified herein by absorbance at OD575, regardless of the method used to determine cell density or units of measurement. One of skill in the art will know how to make the appropriate conversion for any cell culture.

[0082] In embodiments, the final IPTG concentration of the culture is about 0.01 mM, about 0.02 mM, about 0.03 mM, about 0.04 mM, about 0.05 mM, about 0.06 mM, about 0.07 mM, about 0.08 mM, about 0.09 mM, about 0.1 mM, about 0.2 mM, about 0.3 mM, about 0.4 mM, about 0.5 mM, about 0.6 mM, about 0.7 mM, about 0.8 mM, about 0.9 mM, or about 1 mM. In other embodiments, the final IPTG concentration of the culture is from about 0.08 mM to about 0.1 mM, from about 0.1 mM to about 0.2 mM, from about 0.2 mM to about 0.3 mM, from about 0.3 mM to about 0.4 mM, from about 0.2 mM to about 0.4 mM, from about 0.08 to about 0.2 mM, or from about 0.1 to 1 mM. In embodiments, IPTG is at a concentration in the culture medium of from about 0.05 mM to about 2.5 mM.

[0083] In embodiments in which a non-lac-type promoter is used, other inducers or effectors are often used, as described herein and in the literature. In one embodiment, the promoter is a constitutive promoter.

[0084] After addition of the inducer, the culture is often grown for a period of time, e.g., about 24 hours, during which recombinant crisantaspase is expressed. After addition of the inducer, the culture is often grown for about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 36 hours, or about 48 hours. After addition of the inducer to the culture, the culture is grown for about 1 to 48 hours, about 1 to 24 hours, about 10 to 24 hours, about 15 to 24 hours, or about 20 to 24 hours. Cell cultures are often concentrated by centrifugation and the culture pellet is resuspended in a suitable buffer or solution for the subsequent lysis procedure.

[0085] In embodiments, cells are disrupted using a commercially available device for high-pressure mechanical cell disruption (e.g., a Microfluidics Microfluidizer, a Constant Cell Disruptor, a Niro-Soavi homogenizer, or an APV-Gaulin homogenizer). Crisantaspase-expressing cells are often disrupted using, for example, sonication. Any suitable method known in the art for lysing cells is often used to release the soluble fraction. For example, in embodiments, chemical and / or enzymatic cell lysis reagents, such as cell wall lytic enzymes and EDTA, are often used. The use of frozen or previously stored cultures is also contemplated in the methods herein. Cultures are sometimes normalized to an OD600 of about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20.

[0086] Centrifugation can be carried out using any suitable device and method. Centrifugation of cell culture or lysate for the purpose of separating insoluble fraction from insoluble fraction is well known in the art. For example, lysed cells are sometimes centrifuged at 20,800×g for 20 minutes (at 4°C), and the supernatant is removed using manual or automated liquid handling. The pellet (insoluble) fraction is resuspended in a buffered solution, for example, phosphate-buffered saline (PBS), pH 7.4. Resuspension is often carried out using a device such as an impeller connected to an overhead mixer, a magnetic stir bar, or a rocking shaker.

[0087] The "soluble fraction", ie the soluble supernatant obtained after centrifugation of the lysate, and the "insoluble fraction", ie the pellet obtained after centrifugation of the lysate, are the result of lysis and centrifugation of the culture.

[0088] Fermentation method In one embodiment, fermentation is used in the method for producing recombinant crisantaspase. The expression system according to the present disclosure may be cultured in any fermentation format. For example, batch, fed-batch, semi-continuous, and continuous fermentation modes may be employed herein.

[0089] In embodiments, the fermentation medium may be selected from a rich medium, a minimal medium, and a mineral salts medium. In other embodiments, either a minimal medium or a mineral salts medium is selected. In certain embodiments, a mineral salts medium is selected.

[0090] Mineral salts media consist of mineral salts and a carbon source such as glucose, sucrose, or glycerol. Examples of mineral salts media include M9 medium, Pseudomonas medium (ATCC 179), and Davis and Mingioli medium (see B.D. Davis & E.S. Mingioli (1950) J. Bact. 60:17-28). Mineral salts used to make mineral salts media include, for example, potassium phosphate, ammonium sulfate or chloride, magnesium sulfate or chloride, and trace minerals such as calcium chloride, borate, and sulfates of iron, copper, manganese, and zinc. Typically, organic nitrogen sources such as mipeptone, tryptone, amino acids, or yeast extract are not included in mineral salts media. Instead, inorganic nitrogen sources are used, which may be selected from, for example, ammonium salts, aqueous ammonia, and gaseous ammonia. Mineral salts media typically contain glucose or glycerol as a carbon source. Compared to mineral salts media, minimal media often contain mineral salts and a carbon source, but are often supplemented at low levels, e.g., with minimally added amino acids, vitamins, peptones, or other components. Media are often prepared using methods described in the art, e.g., U.S. Patent Application Publication No. 2006 / 0040352, referenced and incorporated by reference above. Details of culture procedures and mineral salts media useful in the methods herein are described by Riesenberg, D. et al., 1991, "High cell density cultivation of Escherichia coli at controlled specific growth rate," J. Biotechnol. 20(1):17-27.

[0091] Fermentation may be carried out at any scale. The expression system according to the present disclosure is useful for recombinant protein expression at any scale. Thus, for example, fermentation volumes at the microliter, milliliter, centiliter, and deciliter scales may be used, with 1 liter and larger fermentation volumes often being used.

[0092] In embodiments, the fermentation volume is about 1 liter or more. In embodiments, the fermentation volume is about 0.5 liters to about 100 liters. In embodiments, the fermentation volume is about 0.5 liters, about 1 liter, about 2 liters, about 3 liters, about 4 liters, about 5 liters, about 6 liters, about 7 liters, about 8 liters, about 9 liters, or about 10 liters. In embodiments, the fermentation volume is about 0.5 liters to about 2 liters, about 0.5 liters to about 5 liters, about 0.5 liters to about 10 liters, about 0.5 liters to about 25 liters, about 0.5 liters to about 50 liters, about 0.5 liters to about 75 liters, about 10 liters to about 25 liters, about 25 liters to about 50 liters, or about 50 liters to about 100 liters. In other embodiments, the fermentation volume is 5 liters, 10 liters, 15 liters, 20 liters, 25 liters, 50 liters, 75 liters, 100 liters, 200 liters, 500 liters, 1,000 liters, 2,000 liters, 5,000 liters, 10,000 liters, or 50,000 liters or more.

[0093] Protein analysis In embodiments, recombinant crisantaspase protein produced by the methods provided herein is analyzed, sometimes by, for example, biolayer interferometry, SDS-PAGE, Western blot, far-Western blot, ELISA, absorbance, or mass spectrometry (e.g., tandem mass spectrometry).

[0094] In some embodiments, the concentration and / or amount of recombinant crisantaspase protein produced is determined by, for example, a Bradford assay, absorbance, Coosmassie staining, mass spectrometry, or the like.

[0095] Protein yields in the insoluble and soluble fractions described herein are often determined by methods known to those skilled in the art, such as capillary gel electrophoresis (CGE) and Western blot analysis. The soluble fraction is often assessed using, for example, biolayer interferometry.

[0096] Asparaginase monomers can form active tetramers, for example, in cell lysates, cell sonicates, and upon further purification. Following expression of recombinant asparaginase in a bacterial expression system, such as an E. coli or Pseudomonas host strain, the recombinant protein can be purified using any suitable method known in the art, for example, to remove host cell proteins. Purification methods include, for example, cation exchange chromatography, anion exchange chromatography, size exclusion chromatography, high-performance liquid chromatography (HPLC), or a combination thereof and / or other known methods. Asparaginase protein purification is described in the literature, for example, U.S. Patent No. 5,310,670, "Method for the purification of Erwinia L-asparaginase," and U.S. Patent No. 8,323,948, "Asparaginases and uses thereof," each of which is incorporated herein by reference in its entirety. Based on expression experiments, type II asparaginase expressed in P. fluorescens exists as a tetrameric asparaginase enzyme that is active in sonicate.

[0097] In embodiments, a measurable characteristic of the quantity of a crude or purified asparaginase sample (e.g., activity, size, length, or other characteristic indicative of an active and / or intact protein) is compared to a measurable characteristic of the same quantity of an asparaginase standard sample (e.g., commercially obtained asparaginase). It is understood that the amount of asparaginase protein in a sample can be determined by any suitable assay known in the art for measuring proteins.

[0098] Useful measures of protein yield include, for example, the amount of recombinant protein per culture volume (e.g., grams or milligrams of protein / liter of culture), the percent or fraction of recombinant protein measured in the insoluble pellet obtained after lysis (e.g., amount of recombinant protein in the extract supernatant / amount of protein in the insoluble fraction), the percent or fraction of soluble recombinant protein, the percent or fraction of active protein (e.g., amount of active protein / amount of protein used in the assay), the percent or fraction of total cellular protein (tcp), amount of protein / cell, and percent dry biomass.

[0099] In embodiments, the methods herein are used to obtain a yield of soluble recombinant crisantaspase protein, e.g., monomer or tetramer, of about 20% to about 90%. In certain embodiments, the yield of soluble recombinant crisantaspase is about 20% total cell protein, about 25% total cell protein, about 30% total cell protein, about 31% total cell protein, about 32% total cell protein, about 33% total cell protein, about 34% total cell protein, about 35% total cell protein, about 36% total cell protein, about 37% total cell protein, about 38% total cell protein, about 39% total cell protein, about 40% total cell protein, about 41% total cell protein, about 42% total cell protein, about 43% total cell protein, about 44% total cell protein, about 45% total cell protein, or about 46% total cell protein. The total cell protein is about 47% total cell protein, about 48% total cell protein, about 49% total cell protein, about 50% total cell protein, about 51% total cell protein, about 52% total cell protein, about 53% total cell protein, about 54% total cell protein, about 55% total cell protein, about 56% total cell protein, about 57% total cell protein, about 58% total cell protein, about 59% total cell protein, about 60% total cell protein, about 65% total cell protein, about 70% total cell protein, about 75% total cell protein, about 80% total cell protein, about 85% total cell protein, or about 90% total cell protein.In some embodiments, the yield of soluble recombinant crisantaspase is about 20% to about 25% total cell protein, about 20% to about 30% total cell protein, about 20% to about 35% total cell protein, about 20% to about 40% total cell protein, about 20% to about 45% total cell protein, about 20% to about 50% total cell protein, about 20% to about 55% total cell protein, about 20% to about 60% total cell protein, about 20% to about 65% total cell protein, about 20% to about 70% total cell protein, about 20% to about 75% total cell protein, about 20% to about 80% total cell protein, about 20% to about 85% total cell protein, about 20% to about 90% total cell protein, about 25% to about 90% total cell protein, about 30% to about 90% total cell protein. The protein may be about 35% to about 90% total cell protein, about 40% to about 90% total cell protein, about 45% to about 90% total cell protein, about 50% to about 90% total cell protein, about 55% to about 90% total cell protein, about 60% to about 90% total cell protein, about 65% to about 90% total cell protein, about 70% to about 90% total cell protein, about 75% to about 90% total cell protein, about 80% to about 90% total cell protein, about 85% to about 90% total cell protein, about 20% to about 40% total cell protein, about 25% to about 40% total cell protein, about 35% to about 40% total cell protein, about 20% to about 35% total cell protein, about 20% to about 30% total cell protein, or about 20% to about 25% total cell protein. In some embodiments, the yield of soluble recombinant crisantaspase is about 20% to about 40% total cellular protein.

[0100] In embodiments, the methods herein are used to obtain a yield of soluble recombinant crisantaspase protein, e.g., monomer or tetramer, of about 20% to about 90% total cellular protein. In certain embodiments, the yield of soluble recombinant crisantaspase is about 1 gram / liter, about 2 grams / liter, about 3 grams / liter, about 4 grams / liter, about 5 grams / liter, about 6 grams / liter, about 7 grams / liter, about 8 grams / liter, about 9 grams / liter, about 10 grams / liter, about 11 grams / liter, about 12 grams / liter, about 13 grams / liter, about 14 grams / liter, about 15 grams / liter, about 16 grams / liter, or about 17 grams / liter. , about 18 g / liter, about 19 g / liter, about 20 g / liter, about 21 g / liter, about 22 g / liter, about 23 g / liter, about 24 g / liter, about 25 g / liter, about 26 g / liter, about 27 g / liter, about 28 g / liter, about 30 g / liter, about 35 g / liter, about 40 g / liter, about 45 g / liter, about 50 g / liter, about 1 g / liter to about 5 g / liter, about 1 g / liter to about 10 g / liter liter, about 10 grams / liter to about 12 grams / liter, about 10 grams / liter to about 13 grams / liter, about 10 grams / liter to about 14 grams / liter, about 10 grams / liter to about 15 grams / liter, about 10 grams / liter to about 16 grams / liter, about 10 grams / liter to about 17 grams / liter, about 10 grams / liter to about 18 grams / liter, about 10 grams / liter to about 19 grams / liter, about 10 grams / liter to about 20 grams / liter Torr, about 10 grams / liter to about 21 grams / liter, about 10 grams / liter to about 22 grams / liter, about 10 grams / liter to about 23 grams / liter, about 10 grams / liter to about 24 grams / liter, about 10 grams / liter to about 25 grams / liter, about 10 grams / liter to about 30 grams / liter, about 10 grams / liter to about 40 grams / liter, about 10 grams / liter to about 50 grams / liter, about 10 grams / liter to about 12 grams / liter,About 12 grams / liter to about 14 grams / liter, about 14 grams / liter to about 16 grams / liter, about 16 grams / liter to about 18 grams / liter, about 18 grams / liter to about 20 grams / liter, about 20 grams / liter to about 22 grams / liter, about 22 grams / liter to about 24 grams / liter, about 23 grams / liter to about 25 grams / liter, about 10 grams / liter to about 25 grams / liter, about 11 grams / liter to about 25 grams / liter, about 12 grams / liter to about 25 grams / liter, about 13 grams / liter to about 25 grams / liter, about 14 grams / liter to about 2 ... grams / liter to about 25 grams / liter, about 15 grams / liter to about 25 grams / liter, about 16 grams / liter to about 25 grams / liter, about 17 grams / liter to about 25 grams / liter, about 18 grams / liter to about 25 grams / liter, about 19 grams / liter to about 25 grams / liter, about 20 grams / liter to about 25 grams / liter, about 21 grams / liter to about 25 grams / liter, about 22 grams / liter to about 25 grams / liter, about 23 grams / liter to about 25 grams / liter, or about 24 grams / liter to about 25 grams / liter. In embodiments, the soluble recombinant protein yield is from about 10 gram / liter to about 13 gram / liter, from about 12 gram / liter to about 14 gram / liter, from about 13 gram / liter to about 15 gram / liter, from about 14 gram / liter to about 16 gram / liter, from about 15 gram / liter to about 17 gram / liter, from about 16 gram / liter to about 18 gram / liter, from about 17 gram / liter to about 19 gram / liter, from about 18 gram / liter to about 20 gram / liter, from about 20 gram / liter to about 22 gram / liter, from about 22 gram / liter to about 24 gram / liter, or from about 23 gram / liter to about 25 gram / liter.or about 18 grams / liter to about 20 grams / liter. In embodiments, the extracted protein yield is about 5 grams / liter to about 15 grams / liter, about 5 grams / liter to about 25 grams / liter, about 10 grams / liter to about 15 grams / liter, about 10 grams / liter to about 25 grams / liter, about 15 grams / liter to about 20 grams / liter, about 15 grams / liter to about 25 grams / liter, or about 18 grams / liter to about 25 grams / liter. In certain embodiments, the yield of soluble recombinant crisantaspase is about 10 grams / liter to about 25 grams / liter.

[0101] In embodiments, the amount of recombinant crisantaspase, e.g., monomer or tetramer, detected in the soluble fraction is about 10% to about 100% of the total amount of recombinant crisantaspase produced, hi embodiments, this amount is about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99%, or about 100% of the total amount of recombinant crisantaspase produced. In embodiments, this amount is about 10% to about 20%, 20% to about 50%, about 25% to about 50%, about 25% to about 50%, about 25% to about 95%, about 30% to about 50%, about 30% to about 40%, about 30% to about 60%, about 30% to about 70%, about 35% to about 50%, about 35% to about 70%, about 35% to about 75%, about 35% to about 95%, about 40% to about 50%, about 40% to about 95%, about 50% to about 75%, about 50% to about 95%, about 70% to about 95%, or about 80 to about 100% of the total amount of recombinant crisantaspase produced.

[0102] In some embodiments, the amount of soluble recombinant asparaginase is expressed as a percentage of the total soluble protein produced in the culture. Data expressed as weight / volume of recombinant asparaginase protein of a cell culture at a given cell density can be converted to data expressed as percent recombinant protein of total cellular protein. For example, it is within the ability of one skilled in the art to convert volumetric protein yield to % total cellular protein, knowing the amount of total cellular protein per volume of cell culture at a given cell density. This number can be determined when 1) the cell weight / volume of the culture at a given cell density and 2) the percent of cell weight contained in total protein are known. For example, an OD550 of 1.0 reports a dry cell weight of 0.5 grams / liter for E. coli ("Production of Heterologous Proteins from Recombinant DNA Escherichia coli in Bench Fermentors," Lin, NS, and Swartz, JR, 1992, METHODS: A Companion to Methods in Enzymology 4:159-168). Bacterial cells are composed of polysaccharides, lipids, nucleic acids, and proteins. E. coli cells are reported to be about 52.4% to 55% protein by references including, but not limited to, Da Silva, N.A., et al., 1986, "Theoretical Growth Yield Estimates for Recombinant Cells," Biotechnology and Bioengineering, Vol. XXVIII:741-746, which estimates that protein accounts for 52.4% by weight of an E. coli cell, and Chief Frederick C. Neidhardt, "Escherichia coli and Salmonella typhimurium Cellular and Molecular Biology," 1987, ed., in Vol. 1, pp. 3-6, which reports the protein content in E. coli to be 55% by dry cell weight.Using the above measurements (i.e., 0.5 grams dry cell weight / liter and protein at 55% cell weight), the amount of total cellular protein per volume of cell culture at an A550 of 1.0 for E. coli is calculated as 275 μg total cellular protein / ml / A550. Calculations of total cellular protein per volume of cell culture based on wet cell weight can use, for example, the determination by Glazyrina et al. (Microbial Cell Factories 2010, 9:42, incorporated herein by reference) that an A600 of 1.0 for E. coli results in 1.7 grams wet cell weight / liter and 0.39 grams dry cell weight / liter. For example, using this wet cell weight and protein as 55% dry cell weight above for dry cell weight comparison, the amount of total cellular protein per volume of cell culture at an A600 of 1.0 for E. coli can be calculated as 215 μg total cellular protein / ml / A600. For Pseudomonas fluorescens, the amount of total cellular protein per volume of cell culture at a given cell density is similar to that found for E. coli. P. fluorescens, like E. coli, is a gram-negative rod. The dry cell weight of P. fluorescens ATCC 11150 reported by Edwards, et al., 1972, "Continuous Culture of Pseudomonas fluorescens with Sodium Maleate as a Carbon Source," Biotechnology and Bioengineering, Vol. XIV, pp. 123-147, is 0.5 grams / liter / A500. This is the same as the weight reported by Lin et al. for E. coli at an A550 of 1.0 for E. coli. Light scattering measurements made at 500 nm and 550 nm are expected to be very similar.The percentage of cell weight that is comprised in total cell protein for P. fluorescens HK44 is described as 55% by, for example, Yarwood, et al., July 2002, "Noninvasive Quantitative Measurement of Bacterial Growth in Porous Media under Unsaturated-Flow Conditions," Applied and Environmental Microbiology 68(7):3597-3605. This percentage is similar or the same as that given for E. coli in the above references.

[0103] In embodiments, the amount of soluble recombinant crisantaspase, e.g., monomer or tetramer, produced is from about 0.1% to about 95% of the total soluble protein produced in the culture. In embodiments, this amount is greater than about 0.1%, 0.5%, 1%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the total soluble protein produced in the culture. In embodiments, this amount is about 0.1%, 0.5%, 1%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the total soluble protein produced in the culture. In embodiments, this amount is from about 5% to about 95%, from about 10% to about 85%, from about 20% to about 75%, from about 30% to about 65%, from about 40% to about 55%, from about 1% to about 95%, from about 5% to about 30%, from about 1% to about 10%, from about 10% to about 20%, from about 20% to about 30%, from about 30% to about 40%, from about 40% to about 50%, from about 50 to about 60%, from about 60% to about 70%, or from about 80% to about 90% of the total soluble protein produced in the culture.

[0104] In embodiments, the amount of soluble recombinant crisantaspase, e.g., monomer or tetramer, produced is about 0.1% to about 50% of dry cell weight (DCW). In embodiments, this amount is greater than about 0.1%, 0.5%, 1%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 45%, or 50% of the DCW. In embodiments, this amount is about 0.1%, 0.5%, 1%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 45%, or 50% of the DCW. In embodiments, this amount is from about 5% to about 50%, from about 10% to about 40%, from about 20% to about 30%, from about 1% to about 20%, from about 5% to about 25%, from about 1% to about 10%, from about 10% to about 20%, from about 20% to about 30%, from about 30% to about 40%, or from about 40% to about 50% of the total soluble protein produced in the culture.

[0105] In embodiments, the yield or amount of cytosolically produced soluble recombinant crisantaspase described by any of these protein measurements (e.g., amount of recombinant protein per culture volume (e.g., grams or milligrams of protein / liter of culture), percent or fraction of recombinant protein measured in the insoluble pellet obtained after lysis (e.g., amount of recombinant protein in extract supernatant / amount of protein in the insoluble fraction), percent or fraction of soluble recombinant protein, percent or fraction of active protein (e.g., amount of active protein / amount of protein used in the assay), percent or fraction of total cellular protein (tcp), amount of protein / cell , and percent dry biomass) is equivalent to or increased relative to the amount of soluble recombinant crisantaspase produced in the periplasm obtained under similar or substantially similar conditions (conditions including, for example, the host cell, the genetic background of the host cell (e.g., deletion of a different protease), the type of promoter in the expression construct, the temperature of growth, the OD of induction if an inducible promoter is used, the amount of inducer (e.g., the amount of IPTG used for induction if the lacZ promoter or a derivative thereof is used), the duration of protein induction, the temperature of growth following addition of the inducer to the culture, the agitation rate of the culture, the method of selection for plasmid maintenance, the volume of the culture in the vessel, and the method of cell lysis). In embodiments, the yield ratio of soluble recombinant crisantaspase produced cytoplasmically to soluble recombinant crisantaspase produced in the periplasm obtained under similar or substantially similar conditions is from about 1:1 (i.e., 1) to about 5:1 (i.e., 5). In embodiments, the yield ratio of cytoplasmically produced soluble recombinant crisantaspase to periplasmically produced soluble recombinant crisantaspase obtained under similar or substantially similar conditions is at least about 1. In embodiments, the yield ratio of cytoplasmically produced soluble recombinant crisantaspase to periplasmically produced soluble recombinant crisantaspase obtained under similar or substantially similar conditions is at most about 5.In embodiments, the yield ratio of cytoplasmically produced soluble recombinant crisantaspase to periplasmically produced soluble recombinant crisantaspase obtained under similar or substantially similar conditions is about 1 to about 1.25, about 1 to about 1.5, about 1 to about 1.75, about 1 to about 2, about 1 to about 2.5, about 1 to about 3, about 1 to about 3.5, about 1 to about 4, about 1 to about 4.5, about 1 to about 5, about 1.25 to about 1.5, about 1.25 to about 1.75, about 1.25 to about 2, about 1.25 to about 2.5, about 1.25 to about 3, about 1.25 to about 3.5, about 1.25 to about 4, about 1.25 to about 4.5, about 1.25 to about 5, about 1.5 to about 1.75, about 1.5 to about 2, about 1.5 to about 2.5, about 1 0.5 to about 3, about 1.5 to about 3.5, about 1.5 to about 4, about 1.5 to about 4.5, about 1.5 to about 5, about 1.75 to about 2, about 1.75 to about 2.5, about 1.75 to about 3, about 1.75 to about 3.5, about 1.75 to about 4, about 1.75 to about 4.5, about 1.75 to about 5, about 2 to about 2.5, about 2 to about 3, about 2 to about 3.5, about 2 to about 4, about 2 to about 4.5, about 2 to about 5, about 2.5 to about 3, about 2.5 to about 3.5, about 2.5 to about 4, about 2.5 to about 4.5, about 2.5 to about 5, about 3 to about 3.5, about 3 to about 4, about 3 to about 4.5, about 3 to about 5, about 3.5 to about 4, about 3.5 to about 4.5, about 3.5 to about 5, about 4 to about 4.5, about 4 to about 5, or about 4.5 to about 5. In embodiments, the yield ratio of cytoplasmically produced soluble recombinant crisantaspase to periplasmically produced soluble recombinant crisantaspase obtained under similar or substantially similar conditions is about 1, about 1.25, about 1.5, about 1.75, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, or about 5.

[0106] Solubility and Activity Protein "solubility" and "activity" are related properties but are generally determined by different means. Protein solubility, particularly of hydrophobic proteins, indicates that hydrophobic amino acid residues are improperly positioned on the exterior of the folded protein. Protein activity, which is often assessed using different methods, for example, as described below, is another indicator of proper protein conformation. As used herein, "soluble, active, or both" refers to proteins that are determined to be soluble, active, or both soluble and active by methods known to those skilled in the art.

[0107] Activity assay Assays for assessing crisantaspase activity are known in the art and include, but are not limited to, fluorimetric, colorimetric, chemiluminescent, spectrophotometric, and other enzyme assays available to those skilled in the art. These assays can be used to compare the activity or efficacy of a crisantaspase preparation with commercial or other crisantaspase preparations.

[0108] In embodiments, activity or efficacy is expressed in terms of percent active protein in the extract supernatant compared to the total amount assayed. This is based on the amount of protein determined to be active by the assay relative to the total amount of protein used by the assay. In other embodiments, activity or efficacy is expressed in terms of the % activity or efficacy level of the protein compared to a standard or control protein. This is based on the amount of active protein in the supernatant extract sample relative to the amount of active protein in the standard sample (where the same amount of protein from each sample is used in the assay).

[0109] In embodiments, the standard or control protein used in an activity or efficacy assay for comparison to the manufactured crisantaspase is the active ingredient in Erwinaze® or any crisantaspase product approved for clinical use and known in the art. In embodiments, the measured activity or efficacy of the manufactured crisantaspase is compared to the activity or efficacy measured in the same amount of standard or control crisantaspase using the same method for measuring crisantaspase activity or efficacy.

[0110] In embodiments, the methods herein further comprise measuring the activity or efficacy of the amount of recombinant crisantaspase protein using an activity or efficacy assay. In embodiments, about 40% to about 100% of the recombinant crisantaspase protein is determined to be active, soluble, or both. In embodiments, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100% of the recombinant crisantaspase protein is determined to be active, soluble, or both. In embodiments, about 40% to about 50%, about 50% to about 60%, about 60% to about 70%, about 70% to about 80%, about 80% to about 90%, about 90% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 40% to about 90% of the recombinant crisantaspase protein. , about 40% to about 95%, about 50% to about 90%, about 50% to about 95%, about 50% to about 100%, about 60% to about 90%, about 60% to about 95%, about 60% to about 100%, about 70% to about 90%, about 70% to about 95%, about 70% to about 100%, or about 70% to about 100% is determined to be active, soluble, or both.

[0111] In other embodiments, about 75% to about 100% of the recombinant crisantaspase is determined to be active, soluble, or both. In embodiments, about 75% to about 80%, about 75% to about 85%, about 75% to about 90%, about 75% to about 95%, about 80% to about 85%, about 80% to about 90%, about 80% to about 95%, about 80% to about 100%, about 85% to about 90%, about 85% to about 95%, about 85% to about 100%, about 90% to about 95%, about 90% to about 100%, or about 95% to about 100% of the recombinant crisantaspase is determined to be active, soluble, or both.

[0112] In embodiments, the methods for producing or expressing a recombinant type II asparaginase described herein further include measuring the activity or efficacy of the produced recombinant type II asparaginase and comparing the measured activity or efficacy of the produced recombinant type II asparaginase to the activity or efficacy measured in the same amount of a control type II asparaginase using the same assay, wherein the measured activity or efficacy of the produced recombinant type II asparaginase is comparable to the activity or efficacy of the control type II asparaginase. In embodiments, comparable activity or efficacy is defined as 100% (also expressed as 1.0), i.e., the activity or efficacy of the produced recombinant type II asparaginase and the control type II asparaginase is equal. In embodiments, the activity or efficacy of the produced recombinant type II asparaginase compared to the control type II asparaginase is about 80% to about 120%. In embodiments, the activity or efficacy is about 85% to about 115%. In embodiments, the activity or efficacy is about 90% to about 110%. In embodiments, the activity or efficacy is from about 70% to about 130%. In embodiments, the activity or efficacy is from about 65% to about 135%. In embodiments, the activity or efficacy of the produced recombinant type II asparaginase compared to a control type II asparaginase is about or at least about 65%, about or at least about 66%, about or at least about 67%, about or at least about 68%, about or at least about 69%, about or at least about 70%, about or at least about 71%, about or at least about 72%, about or at least about 73%, about or at least about 74%, about or at least about 75%, about or at least about 75%, about or at least about 76%, about or at least about 77%, about or at least about 78%, about or at least about 79%, about or at least about 80%, about or at least about 81%, about or at least about 82%, about or at least about 83%, about or at least about 84%, about or at least about 85%, about or at least about 86%, about or at least about 87%, about or at least about 88%, about or at least about 89%, about or at least about 90%,about or at least about 91%, about or at least about 92%, about or at least about 93%, about or at least about 94%, about or at least about 95%, about or at least about 96%, about or at least about 97%, about or at least about 98%, about or at least about 99%, about or at least about 100%, about or at least about 101%, about or at least about 102%, about or at least about 103%, about or at least about 104%, about or at least about 105%, about or at least about 106%, about or at least about 107%, about or at least about 108%, about or at least about 109%, about or at least about 110%, about or at least about 111%, about or at least about 112%, about or at least about 113%, about or at least about 114%, about or at least about 115%, about or at least about 116%, about or at least about 117%, about or at least about 118%, about or at least about 119%, about or at least about 120%, about or at least about 121%, about or at least about 122%, about or at least about 123%, about or at least about 124%, about or at least about 125%, about or at least about 126%, about or at least about 127%, about or at least about 128%, about or at least about 129%, about or at least about 130%, about or at least about 131%, about or at least about 132%, about or at least about 133%, about or at least about 134%, or about or at least about 135%. In embodiments, the activity or efficacy of the produced recombinant type II asparaginase compared to a control type II asparaginase is about 68% to about 132%, about 70% to about 130%, about 72% to about 128%, about 75% to about 125%, about 80% to about 120%, about 85% to about 115%, about 65% to about 110%, about 68% to about 110%, about 70% to about 110%, about 72% to about 110%, about 78% to about 110%, about 80% to about 110%, about 90% to about 110%, about 95% to about 105%, about 85% to about 110%, about 90% to about 110%, about 95% to about 110%, about 96% to about 110%, about 97% to about 110%, about 98% to about 110%, about 99% to about 110%, about 100% to about 110%,About 65% to about 105%, about 68% to about 105%, about 70% to about 105%, about 72% to about 105%, about 80% to about 105%, about 85% to about 105%, about 90% to about 105%, about 95% to about 105%, about 96% to about 105%, about 97% to about 105%, about 98% to about 105%, about 99% to about 105%, about 100% to about 105%, about 65% to about 100%, about 68% % to about 100%, about 70% to about 100%, about 72% to about 100%, about 75% to about 100%, about 78% to about 100%, about 80% to about 100%, about 81% to about 100%, about 82% to about 100%, about 83% to about 100%, about 84% to about 100%, about 85% to about 100%, about 86% to about 100%, about 87% to about 100%, about 88% to about 100%, about 89% to about 100%, about 90% to about 100%, about 91% to about 100%, about 92% to about 100%, about 93% to about 100%, about 94% to about 100%, about 95% to about 100%, about 96% to about 100%, about 97% to about 100%, about 98% to about 100%, about 99% to about 100%, about 95% to about 99%, about 96% to about 99%, about 97% to about 99%, about 70% to about 135%, about 7 5% to about 135%, about 80% to about 135%, about 85% to about 135%, about 90% to about 135%, about 75% to about 130%, about 80% to about 130%, about 85% to about 130%, about 90% to about 130%, about 80% to about 125%, about 85% to about 125%, about 90% to about 125%, about 85% to about 120%, about 90% to about 120%, or about 95% to about 120%.

[0113] Example The following examples are given for the purpose of illustrating various embodiments of the present disclosure and are not intended to limit the disclosure in any way. The examples, together with the methods described herein, are presently representative embodiments and are illustrative and not intended to limit the scope. Variations therein and other uses encompassed within the spirit of the disclosure as defined by the scope of the claims will occur to those skilled in the art. [Example]

[0114] Example 1: Project Overview The project began by constructing expression strains. The gene encoding the crisantaspase protein was optimized for expression in P. fluorescens and synthesized and ligated into each of 40 expression vectors, facilitating one cytoplasmic and 39 periplasmic crisantaspase protein expression strategies. Plasmids were transformed into 24 P. fluorescens host strains (consisting of protease-deficient (PD), folding modulator-overexpressing (FMO), protease-deficient plus folding modulator-overexpressing (PD / FMO), and wild-type (WT) strains), resulting in 240 unique expression strains.

[0115] Each strain was grown and induced in duplicate in a 96-well format according to a high-throughput (HTP) growth and expression protocol. Initial screening of 240 expression strains at the 96-well scale demonstrated that high expression of soluble crisantaspase protein monomer could be achieved. Based on SDS-CGE analysis of samples from the top 15 strains identified in the 96-well screening, the estimated titers of soluble crisantaspase monomer ranged from approximately 0.7 to 1.9 g / L when compared to an E. coli L-asparaginase (Sigma) standard curve. Shake flask-grown samples from selected expression strains were further analyzed to confirm activity (using a commercially available activity assay kit) and intact mass (by LC-MS). Based on the high titer and no detectable degradation of monomeric crisantaspase protein as determined by SDS-CGE analysis, expression strain STR55978 was selected for fermentation evaluation at a 2 L scale.

[0116] At a 2 L fermentation scale, selected STR55978-expressing strains were grown under eight different induction conditions. Induction variables included wet cell weight, IPTG concentration, pH, and temperature at induction. Capture chromatography was performed on lysate samples from selected fermentation pastes, and the resulting capture eluates were then analyzed using multiple methods to assess protein identity, activity, and purity. [Example]

[0117] Example 2: Materials and Methods Design of a synthetic crisantaspase gene for optimal expression DNA encoding the crisantaspase peptide sequence (Figure 2, SEQ ID NO:2) was designed to reflect appropriate codon usage for P. fluorescens. A DNA region containing a unique restriction enzyme site (SapI or LguI) was added upstream of the crisantaspase coding sequence, designed for direct fusion in frame with the secretion leader coding sequence present in the expression vector. A DNA region containing 3 stop codons and a unique restriction enzyme site (SapI) was added downstream of the coding sequence. The synthetic gene, designated pJ201:226734, was produced by DNA2.0 Inc.

[0118] Construction of crisantaspase protein expression plasmid Standard cloning methods were used to construct the expression plasmids used in the HTP Tier 1 expression strategy (or plasmid) screen. Plasmid pJ201-226734, containing the optimized crisantaspase protein coding sequence, was obtained from DNA2.0. The pJ201-226734 plasmid was digested with the restriction enzyme SapI, and the 993-bp fragment containing the optimized crisantaspase gene was subcloned into 40 total expression vectors to facilitate one cytoplasmic and 39 periplasmic expression strategies. Periplasmic expression parameters included 37 different periplasmic leaders and two ribosome binding site (RBS) affinities. The insert and vector were ligated overnight with T4 DNA ligase (New England Biolabs, M0202S) and electroporated into a competent P. fluorescens host strain in a 96-well format. The resulting plasmids were designated p743-001 to p743-040, as listed in Table 5. Two additional plasmids, p743-041 and p743-042, were included in the host strain screening. The p743-042 plasmid, like the p743-001 plasmid, was designed for expression of the cytoplasmic crisantaspase protein. However, the p743-042 plasmid was later constructed using a PCR-based method to remove the extra alanine codon immediately following the initiator methionine codon in the crisantaspase coding sequence of plasmid p743-001. [Table 5-1] [Table 5-2]

[0119] Growth and expression in 96-well format For expression plasmid screening (HTP Tier 1), ligation mixtures of each of the crisantaspase expression plasmids (Table 5) were transformed into P. fluorescens host strains DC454 (PyrF-deficient, wild-type protease (WT)) and DC441 (pyrF-, Lon-, and HslUV-deficient (PD)) cells. Twenty-five microliters of competent cells were thawed and transferred to a 96-multiwell Nucleovette® plate (Lonza VHNP-1001), and the ligation mixture was added to each well. Nucleofector TM 96-well Shuttle TM Cells were electroporated using a 96-well deep-well plate electroporator (Lonza AG). Cells were then transferred to a 96-well deep-well plate containing 400 μl of M9 salts 1% glucose medium and trace elements (Teknova). The 96-well plate (seed plate) was incubated at 30°C with shaking for 48 hours. Ten microliters of seed culture were transferred in duplicate to a 96-well deep-well plate, each well containing 500 μl of HTP medium (Teknova), supplemented with trace elements and 5% glycerol, and incubated for 24 hours as before. Isopropyl-β-D-1-thiogalactopyranoside (IPTG) was added to each well at a final concentration of 0.3 mM at 24 hours to induce target protein expression. Mannitol (Sigma, M1902) was added to each well at a final concentration of 1% to induce folding modulator expression in the folding modulator-overexpressing strains. Growth was monitored by measuring cell density by optical density at 600 nm (OD600) 24 hours after induction. At 24 hours after induction, cells were harvested, diluted 1:3 in 1X PBS to a final volume of 400 μl, and then frozen.

[0120] For host strain screening (HTP Tier 2), DNA from 10 HTP Tier 1 strains with selected expression plasmids (Table 6) was transformed into 24 P. fluorescens host strains (Table 7), including the wild-type (parent) DC454 (WT) strain, a protease-deficient (PD) strain, a folding modulator overexpressor (FMO) strain, and a protease-deficient plus folding modulator overexpressor (PD / FMO) strain. The folding modulator, if present, was encoded on a second plasmid, and expression was driven by the P. fluorescens native mannitol-inducible promoter. The 240 host strain screen transformations were performed as follows: 25 microliters of P. fluorescens host strain competent cells were thawed and transferred into a 96-multiwell Nucleovette® plate, and 10 μl of plasmid DNA (10 ng) was added to each well. Cells were electroporated, cultured, induced in HTP format, and harvested as described for the plasmid expression screening above. [Table 6] [Table 7]

[0121] Construction of P. fluorescens asparaginase-deficient host strain / construction of gene knockout plasmid A BLAST search of the P. fluorescens MB214 genome sequence using the crisantaspase protein amino acid sequence (Figure 2) as input resulted in the output of two protein-coding genes (PEGs) that showed significant alignment: PEG.3886 (L-asparaginase EC 3.5.1.1 type II, SEQ ID NO: 62); E value 5e-85 and PEG.5048 (L-asparaginase EC 3.5.1.1, SEQ ID NO: 61); E value 3e-05. Cloned deletion constructs for each native L-asparaginase gene were initiated by synthesizing DNA sequence fragments containing fusions of the upstream and downstream flanking regions for each gene, leaving only the start and stop codons of the gene targeted for deletion. Genewiz Inc. (South Plainfield, NJ) completed the synthesis of sequence fragments delPEG3886 (1,107 bp) and delPEG5048 (801 bp), which were then blunt-end ligated into the SrI site of vector pDOW1261-24 to produce deletion plasmids pFNX3970 and pFNX3969, respectively.

[0122] Construction of native L-asparaginase-deficient host strain Chromosomal deletion of each gene was performed sequentially in the selected host strain using the following method: The deletion plasmid was electroporated into a P. fluorescens host strain containing a chromosomal deletion in the pyrF gene, involved in uracil (pyrimidine) biosynthesis. The deletion plasmid contains the PyrF coding sequence but is unable to replicate in P. fluorescens cells. Electroporated cells were plated onto M9 salt agar plates supplemented with 1% glucose and 250 μg / mL proline (if the host strain is proline auxotrophic). The resulting clones are capable of synthesizing uracil through an integration event that recombines the entire deletion plasmid into the chromosome at one of two homologous regions within the genome. To perform a second homologous recombination between the integrated plasmid and the chromosome, thereby selecting for cells that retain the deletion, the plasmid-integrated strain was grown to stationary phase in 3 mL LB medium supplemented with 250 μg / mL uracil and 250 μg / mL proline (if the host strain is proline auxotrophic). The cells were then plated onto LB uracil (250 μg / mL) plus 250 μg / mL proline (if the host strain was a proline auxotroph) agar plates, also containing 500 μg / mL 5-fluoroorotic acid (5-FOA) (Zymo Research). Cells that lose the integrated plasmid via recombination are also expected to lose the pyrF gene and thus be resistant to 5-FOA, which is otherwise converted into a toxic compound that inhibits cell growth. Single colonies showing good growth in the presence of 5-FOA (500 μg / mL) were then picked and grown in 3 mL liquid M9 minimal medium containing 1% glucose supplemented with 250 μg / mL uracil and 250 μg / mL proline (if the host strain was a proline auxotroph), generating cultures for storage as glycerol stocks and as templates for diagnostic PCR and sequencing reactions.

[0123] Confirmation of chromosomal deletion of the native L-asparaginase gene Diagnostic PCR reactions were used to screen for the desired native L-asparaginase gene chromosomal deletion using primers annealing to a chromosomal region outside the synthetic gene deletion sequence cloned into the knockout plasmid. DNA sequencing of the generated PCR products was used to determine that the desired native L-asparaginase gene deletion had occurred as expected, without unwanted mutations or DNA rearrangements.

[0124] Growth and expression of crisantaspase-expressing strains in shake flasks Three crisantaspase-expressing strains and two null strains (P. fluorescens wild-type strain DC454 null and P. fluorescens native L-asparaginase type 1 and 2-deficient strain PF1433 null) were selected for shake flask expression scale-up experiments. The null strains carried an expression vector lacking the crisantaspase protein coding sequence. PF1433 (PyrF-, AspG1-, and AspG2-deficient) was constructed by sequential deletion of the aspG2 and aspG1 genes in the host strain DC454 (PyrF-deficient).

[0125] Each expression strain was inoculated into 2 mL of M9 salts 1% glucose (Teknova). The cultures were incubated at 30°C with shaking for 24 hours. A 2% inoculum of the overnight-grown culture for each expression strain was subcultured into 2 x 200 mL HTP-YE medium supplemented with Trace Elements (Teknova). The flasks were incubated at 30°C with shaking for 24 hours. Prior to induction, the OD600 of the flasks was recorded by diluting 20 μL with 980 μL of water. Isopropyl-β-D-1 thiogalactopyranoside (IPTG) was added to each flask to a final concentration of 0.3 mM to induce expression of the crisantaspase protein. The flasks were incubated at 30°C with shaking for 24 hours. For each strain, two culture flasks were combined and harvested, and the OD600 of the flasks was recorded. After induction, 400 µL was diluted 1:3 with 1X PBS and then frozen for reducing SDS-CGE and further analysis. For each strain, ~400 mL of culture was centrifuged (15,900 x g for 30 min at 4 °C). After recording the wet weight, the pellet was frozen at -80 °C.

[0126] 2L scale fermentation and sampling Inoculum for 2L-scale fermentations (approximately 1L final fermentation volume) was generated by inoculating shake flasks containing 600mL of chemically defined medium supplemented with yeast extract and glycerol with frozen culture stocks of the selected strains. After 16 to 24 hours of incubation with shaking at 30°C, equal portions of the shake flask culture were then transferred to each of eight multiplex fermentation systems containing chemically defined medium designed to support high biomass. In 2L fermentors, the cultures were operated in glycerol fed-batch mode under controlled conditions for pH, temperature, and dissolved oxygen. The fed-batch high-cell-density fermentation process consisted of a growth phase followed by an induction phase, initiated by the addition of IPTG once the culture reached the target biomass (wet cell weight). Conditions during the induction phase were varied according to the experimental design. The induction phase of the fermentation was allowed to proceed for approximately 24 hours. Analytical samples were collected from the fermentors to determine cell density (optical density at 575nm) and then frozen for subsequent analysis to determine the expression level of the target gene. At the end of 24 hours post-induction, the whole fermentation broth from each vessel was harvested by centrifugation at 15,900 xg for 60 to 90 minutes. The cell paste and supernatant were separated, and the paste was retained and frozen at -80°C.

[0127] Sample preparation Soluble fractions were prepared by sonication followed by centrifugation. Culture broth samples (400 μL) were sonicated using a Cell Lysis Automated Sonication System (CLASS, Scinomix) with a 24-probe tip horn under the following settings: 20 pulses per well with 10 seconds per pulse and 10 seconds between pulses at 60% power (Sonics Ultra-Cell). The lysate was centrifuged at 5,500 x g for 15 minutes (4°C), and the supernatant was collected (soluble fraction).

[0128] SDS-CGE analysis Protein samples were analyzed by microchip SDS capillary gel electrophoresis using a LabChip GXII instrument (PerkinElmer) with HT Protein Express chips and corresponding reagents (part numbers 760528 and CLS760675, respectively, PerkinElmer). Samples were prepared according to the manufacturer's protocol (Protein User Guide Document No. 450589, Rev. 3). Briefly, in a 96-well polypropylene conical well PCR plate, 4 μL of sample was mixed with 14 μL of sample buffer and 70 mM DTT reducing agent, heated at 95°C for 5 minutes, and diluted by adding 70 μL of DI water. Null-strain lysate was run in parallel with the test samples. Data were analyzed and gel-like images were generated using LabChip GX v.4.0.1425.0.

[0129] SDS-PAGE analysis The identity and purity of asparaginase were determined using SDS-PAGE analysis. Test samples were diluted in PBS and loading buffer plus 25 mM DTT before heating at 70°C for 10 minutes. Samples were loaded onto a 12% Bis-Tris gel at 2 or 4 μg / well. Samples were separated in 1x MOPS running buffer at a constant voltage of 200 V until the dye front migrated down the length of the gel (approximately 1 hour). After electrophoresis, gels with 1 or 2 μg / well were stained with Oriole fluorescent gel stain (Bio-Rad) for 1 hour, and gels with a 4 μg / well load were stained with GelCodeBlue (ThermoFisher) overnight. After staining, the fluorescently stained gels were transferred to water and then imaged using a GelDocEZ system (Bio-Rad). The blue-stained gels were transferred to water for approximately 1.5 to 2 hours for destaining and then imaged using the GelDocEZ system.

[0130] Western blot The identity of asparaginase was determined using Western blot. Test samples were diluted in loading buffer with PBS and the reducing agent DTT before heating at 70°C for 10 minutes. Samples were then loaded at 1 μg / well and separated on a 12% Bis-Tris gel, similar to SDS-PAGE run conditions. Following electrophoresis, proteins were transferred to a nitrocellulose membrane at 25 V and 125 mA for 90 minutes. Blocking was performed overnight at 2 to 8°C using Blocker Casein (Thermo) and followed by three washes with PBST (Sigma). The membrane was then incubated with rabbit anti-crisantaspase polyclonal antibody diluted 1:5000 in 9 parts PBST and 1 part Blocker Casein for 1 hour at room temperature at 50 rpm. Following three PBST washes, goat anti-rabbit IgG conjugated to Horseradish Peroxidase (HRP) was diluted 1:5000 in a 9:1 PBST:casein solution and incubated for 1 hour at room temperature at 50 rpm. Following three further washes, the antigen-antibody complexes were revealed by the addition of DAB substrate (Thermofisher). After bands were clearly visible, the reaction was stopped by transferring the membrane into water, and the membrane was imaged using a GelDocEZ imaging system (Bio-Rad).

[0131] SE-HPLC SE-HPLC for the samples was performed on an Agilent Technologies 1100 HPLC system equipped with a DAD UV detector. The mobile phase was 50 mM sodium phosphate, 200 mM NaCl, pH 7.0. Dilution of the stock drug product to 1 mg / mL with 1x PBS allowed 50 μg of each sample to be loaded onto a Phenomenex SEC-s4000 (7.8 mm ID x 300 mm, 5 μm) HPLC analytical column with a Phenomenex BioSep SEC s4000 HPLC guard cartridge. UV absorbance was monitored at 215 nm at a flow rate of 1.0 mL / min. Column and sample temperatures were not controlled for a total run time of 18 minutes. Area % purity was calculated using OpenLab software. Peak integration was performed in standard tangent skim mode with zero values ​​for all skim integration events. Baseline correction was set to no penetration with a peak to valley ratio of 500. The first integration event included gradient sensitivity of 1, peak width of 0.25, area exclusion of 1, height exclusion of 10, and shoulder integration set to DROP. Integration was inhibited from 0 to 7 minutes and from 11.15 minutes to the end of the run. The baseline was also set to Baseline Hold at 9 minutes.

[0132] Intact mass analysis of target proteins Soluble lysate samples were filtered / desalted into PBS before intact mass analysis by liquid chromatography coupled to mass spectrometry (LC-MS). Samples purified by one or two column steps were run cleanly.

[0133] Samples were subjected to LC-MS analysis using an interconnected autosampler, column heater, UV detector, and HPLC (Waters Acquity) coupled to a Q-Tof micro-mass spectrometer (Waters Xevo) with an electrospray interface. A CN column (Zorbax 5 μm, 300SB-CN, Agilent) fitted with a guard column (Zorbax 5 μm, 300SB-CN, 4.6 x 12.5 mm, Agilent) was used for separation at 50 °C. The HPLC buffers used were Buffer A (0.1% formic acid) and Buffer B (100% acetonitrile with 0.1% formic acid). A general gradient was used. After loading at 5% B and 95% buffer A, the protein sample was subjected to the following reverse-phase gradient at 0.2 mL / min: the column was subjected to 5-60% B in 45 min, followed by a 2 min gradient from 60% to 95% B, followed by a 3 min gradient to 95% B, and ending at 5% B in 5 min (60 min total method time).

[0134] Prior to MS, UV absorbance was collected from 180–500 nm. The MS source was set to positive. MS scans were performed using the m / z range of 600–2600 at 2 scans per second. MS and UV data were analyzed using MassLynx software (Waters). UV chromatograms of MS total ion current (TIC) were generated. MS spectra of target peaks were summed. These spectra were deconvoluted using MaxEnt1 (Waters) scanning at 1 Da resolution per channel over a molecular weight range of 30,000–40,000. [Example]

[0135] Example 3: CrisantaspazetiA 1 expression plasmid screening in 96-well format For expression plasmid screening, crisantaspase protein coding sequences optimized for expression in P. fluorescens were designed and synthesized as described in Example 2 (Figure 2). Plasmids were constructed carrying the optimized crisantaspase gene fused to 37 different P. fluorescens secretion leaders and two ribosome binding site (RBS) affinities (Table 5). To localize the crisantaspase protein within the cell cytoplasm, an additional plasmid was constructed to express the crisantaspase protein without a periplasmic leader. A representative plasmid map (p743-042) is shown in Figure 3. Target expression was driven from the Ptac promoter, and translation initiated from a highly active ribosome binding site (RBS). The resulting 40 plasmids were transformed into two P. fluorescens host strains, DC454 (WT) and DC441 (PD), to produce 80 expression strains for Tier 1 (expression strategy) screening. Ranking of expression strategies was based on SDS-CGE estimated titers of crisantaspase monomer.

[0136] As described in Example 2, the resulting cultures from 80 transformations (40 expression strategies × 2 host strains) were grown in 96-well plates. Sonicate fraction samples from whole broth cultures harvested 24 hours after induction were analyzed by SDS-CGE. Induced protein expression was quantified, consistent with the expected molecular weight of crisantaspase monomer (35 kDa), which comigrated with E. coli L-Asp (Sigma Product). SDS-CGE quantification of reduced samples was completed by comparing the induced band to an E. coli L-Asp standard curve. The 20 highest-yielding samples from both the DC454 and DC441 host strains were ranked based on estimated soluble crisantaspase monomer titers (Table 8). Figure 1 shows an SDS-CGE gel-like image generated from the analysis of the 96-well culture soluble sonicate samples. Table 8 shows 24-hour post-induction (124) titers estimated by SDS-CGE analysis of reduced soluble sonicates (single rep) and quantified by Labchip® internal ladder for plasmids expressed in DC454 (left table) and DC441 (right table) host strains. Also shown are the secretion leader fusions produced from each p743 expression plasmid.

[0137] [Table 8-1] [Table 8-2]

[0138] The six plasmids and integrated secretion leaders (p743-013 (FlgI leader), p743-038(8484), p743-020(LolA), p743-018(DsbC), p743-009(Ibp-S31A) and p743-034(5193)) observed in the top 10 highest yielding expression strains from both DC454 and DC441 host strains are listed in Table 8. **Additionally, the p743-001 expression plasmid, designed for cytoplasmic expression of crisantaspase protein, ranked among the top two highest soluble yields for both hosts. From both host strains combined, the top 10 highest soluble titers ranged from 525 to 1,523 μg / mL. Insoluble yields were low for all expression plasmids, with the highest insoluble yield achieved at 230 μg / mL using the p743-013 plasmid. Observation of SDS-CGE banding patterns (Figure 1) indicates that the most complete secretory leader processing (removal upon export to the periplasm) occurred using the p743-013, p743-033 (leader O), p743-038, p743-009, and p743-018 expression plasmids, while the p743-016 and p743-017 plasmids were observed to produce prominent low-molecular-weight cleavage products. The 10 expression plasmids shown in Table 6 were selected for subsequent host strain screening at the 96-well HTP scale based on SDS-CGE-estimated high soluble titers. The 10 selected expression strategies were then combined with 24 unique host strains that could further influence crisantaspase protein titer and quality. [Example]

[0139] Example 4: Crisantaspazetia 2 host strain screening in 96-well format The 10 selected crisantaspase expression strategies, or plasmids, identified in the Tier 1 expression strategy screen were transformed into 240 P. fluorescens host strains (Table 7), including 11 protease-deficient (PD) strains, 8 protease-deficient plus folding modulator overexpressor (PD / FMO) strains, 4 FMO strains, and 1 wild-type strain. The folding modulator, if present, was encoded on a second plasmid, and expression was driven by the P. fluorescens native mannitol-inducible promoter. The recovery of 24 host strains was selected to reduce proteolysis and / or promote protein solubility. The DC454 (WT) and DC441 (PD) strains, which were used as host strains in the expression strategy screen, were also included in the 24 host strain screen.

[0140] Twenty-four host strains harboring each of the 10 selected crisantaspase expression plasmids (a total of 240 expression strains) were grown in duplicate in a 96-well plate (HTP) as described in Example 2. Samples taken 24 hours after induction were analyzed by SDS-CGE to detect and quantify soluble and insoluble crisantaspase protein expression. Screening of reduced soluble and insoluble fractions by SDS-CGE was performed on single replicates from all 240 strains. SDS-CGE detected induced bands that comigrated with an E. coli L-Asp standard (Sigma), and relative titers were interpolated from the E. coli L-Asp standard curve. Table 9 lists the 15 samples that exhibited the highest estimated crisantaspase whole cell (soluble and insoluble) monomer titers, ranging from 1,453 to 2,362 μg / mL.

[0141] Results from SDS-CGE screening of single HTP growth replicates are shown in Table 9. Each row identifies the crisantaspase-expressing strain ID, the host strain used, the host strain phenotype (PD = protease-deficient; FMO = folding modulator overexpressor), and the expression plasmid used. Reported titers are based on comparison to an E. coli L-Asp (Sigma) standard curve and are sorted based on the total cell (soluble plus insoluble) crisantaspase protein estimated titer. [Table 9]

[0142] Strain STR55978 harbors the cytoplasmic crisantaspase expression plasmid p743-042 in the background of a wild-type P. fluorescens host strain containing a chromosomal deletion of native L-asparaginase types 1 and 2 (PF1433 host strain). Strains STR55901, STR55891, STR55896, and STR55906 were constructed from either the PF1285(PD) or PF1332(PD) host strains harboring either the p743-013 or p743-038 expression plasmids. Based on the observed high soluble and total crisantaspase titers, these four strains were reconstructed as native L-asparaginase-deficient versions. The STR55978 crisantaspase-expressing strain, expressing wild-type crisantaspase in the p743-042 plasmid in the L-asparaginase-deficient host strain PF1433, was selected for screening induction conditions at a 2 L fermentation scale. [Example]

[0143] Example 5: Crisantaspase shake flask expression Shake flask expression (200 mL) was performed after transformation of selected expression plasmids p743-042, p743-033, and p743-038 into the asparaginase-deficient host strain PF1433, generating expression strains STR55978, STR55979, and STR55980, respectively. To assess whether deletion of the endogenous asparaginase gene from the P. fluorescens chromosome produced an observable growth penalty, shake flask expression work was completed in parallel with construction of the asparaginase-deficient crisantaspase expression host strain (see Example 4). Additionally, lysates generated from shake flask samples were used for initial activity analysis and confirmation of intact mass by LC-MS analysis. Table 10 shows the results from SDS-CGE analysis of the reduced soluble and insoluble sonicates produced from the shake flask expression analysis. [Table 10]

[0144] Table 10 shows the average estimated titers determined by SDS-CGE analysis of soluble and insoluble sonicate fractions (10 different replicates) of three crisantaspase-expressing strains constructed using the PF1433 host strain (native asparaginase-deficient, wild-type strain) analyzed at a 200 mL working volume shake flask scale. SDS-CGE titers were estimated based on comparison with an E. coli L-Asp (Sigma) standard curve. SDS-CGE gel-like images obtained from both soluble and insoluble sonicate analysis of each strain are shown in Figure 4.

[0145] Analysis included shake flask growth from two null strains: STR55982 and DC432. Strain DC432 harbors plasmid pDOW1169, which does not contain the crisantaspase coding region, in a wild-type P. fluorescens host strain. STR55982 harbors plasmid pDOW1169 in host strain PF1433, which contains a chromosomal deletion of both native asparaginase coding sequences. All three crisantaspase-expressing strains produced primarily soluble crisantaspase protein expression, with strain STR55978 achieving the highest soluble titer, up to 14 g / L. Furthermore, no growth penalty was observed as all three crisantaspase-expressing strains achieved similar cell densities (OD600 = 23.0, 27.0, and 27.8) 24 hours post-induction when compared to the STR55982 and DC432 null strains, which gave OD600s of 21.7 and 23.7, respectively, 24 hours post-induction.

[0146] Soluble sonicate samples produced from each of the five shake-flask expression strains were analyzed for asparaginase activity using a commercial kit (Asparaginase Activity Assay Kit) purchased from Sigma, according to the manufacturer's instructions. This kit measures activity using a coupled enzyme reaction that produces a colorimetric end product proportional to the aspartic acid produced. E. coli asparaginase type II, obtained from Sigma, was spiked into STR55982 null lysate as a positive control (last row, Table 11).

[0147] The activity results are shown in Table 11. [Table 11]

[0148] While both null samples showed no measurable activity at a 1:25,000 dilution factor, soluble sonicate samples from strains STR55978, STR55979, and STR55980 diluted 1:25,000 showed comparable activity to a similarly diluted STR55982 null strain sample spiked with 250 μg / mL E. coli L-asparaginase from Sigma. These activity results using a commercially available kit indicate that the crisantaspase protein expressed in P. fluorescens can readily form active tetrameric asparaginase enzyme within the sonicate produced.

[0149] Table 12 shows LC-MS intact mass results from analysis of crisantaspase protein from soluble sonicates produced by strains STR55978, STR55979, and STR55980 in shake flasks. The observed molecular weight of the crisantaspase protein from each strain (35,053 Da) is consistent with the theoretical molecular weight (35,054.2 Da), indicating that all three strains produce the expected amino acid sequence and complete processing or removal of the secretory leader, if present. Sigma E. coli L-Asp was analyzed as a control. Figure 7 shows the mass spectrometry readout for STR55978. [Table 12] [Example]

[0150] Example 6: 2L fermentation evaluation The cytoplasmic expression strain STR55978, an endogenous asparaginase-deficient strain, was evaluated under eight different fermentation induction conditions in a design of experiments (DOE) format. The conditions varied included WCW (g / g), IPTG concentration, pH, and temperature at induction. Targeted induction setpoints in this factorial DOE included a cell density of 0.2-0.4 g / g wet cell weight, 0.08-0.2 mM IPTG, a post-induction pH of 6.5-7.2, and a post-induction culture temperature of 25-32°C. Growth measured by wet cell weight for each condition is shown in Figure 5. Soluble crisantaspase titers ranged from 10-24 g / L or 20-40% total cell protein (Table 13). Recombinant crisantaspase expression measured by reduced soluble SDS-CGE is shown in Figure 6. [Table 13] [Table 14-1] [Table 14-2] [Table 14-3] [Table 14-4] [Table 14-5] [Table 14-6] [Table 14-7] [Table 14-8] [Table 14-9] [Table 14-10]

[0151] While preferred embodiments of the present disclosure have been shown and described herein, such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will occur to those skilled in the art without departing from the disclosure. It should be understood that various alternatives to the embodiments of the disclosure described herein may be employed in practicing the methods herein. It is intended that the following claims define the scope of the invention, and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Claims

1. 10. A method for producing a recombinant type II asparaginase, comprising culturing a Pseudomonadales fluorescens host cell in a culture medium that is deficient in expression of one or more native asparaginases, and expressing a recombinant type II asparaginase from an expression construct comprising a nucleic acid encoding the recombinant type II asparaginase in the cytoplasm of the Pseudomonadales fluorescens host cell, wherein the recombinant type II asparaginase comprises an amino acid sequence at least 90% identical to SEQ ID NO:1, the one or more native asparaginases are a type I asparaginase and a type II asparaginase, the expression construct comprises a ribosome binding site comprising a sequence set forth in SEQ ID NO:50, the nucleic acid encoding the recombinant type II asparaginase comprises a sequence at least 90% identical to SEQ ID NO:2, and the recombinant type II asparaginase is produced in the cytoplasm in a soluble form with a yield of 20% to 40% total cellular protein (TCP).

2. 2. The method of claim 1, wherein the recombinant type II asparaginase is produced in the cytoplasm at a yield of 10 g / L to 25 g / L.

3. 10. The method of claim 1, further comprising measuring the activity of the amount of soluble recombinant type II asparaginase produced using an activity assay.

4. 2. The method of claim 1, wherein the recombinant type II asparaginase is Erwinia chrysanthemi L-asparaginase type II (crisantaspase).

5. 2. The method of claim 1, wherein the recombinant type II asparaginase comprises the amino acid sequence set forth in SEQ ID NO:

1.

6. 10. The method of claim 1, wherein the host cell is deficient in expression of one or more proteases; overexpresses one or more folding modulators; or both.

7. 4. The method of claim 3, further comprising comparing the measured activity of the produced recombinant type II asparaginase with the measured activity of the same amount of a control type II asparaginase using the same activity assay, wherein the measured activity of the produced recombinant type II asparaginase is comparable to the activity of the control type II asparaginase.

8. 10. The method of claim 1, wherein the recombinant type II asparaginase is modified to increase its half-life in the patient.

9. 10. The method of claim 1, wherein the recombinant type II asparaginase produced is used to treat a patient having a neoplastic condition.

10. 10. The method of claim 9, wherein the neoplastic condition is acute lymphoblastic leukemia, acute myeloid leukemia, or non-Hodgkin's lymphoma.

11. 9. The method of claim 8, wherein the recombinant type II asparaginase is modified by pegylation.

12. 7. The method of claim 6, wherein the host cell is HslUV protease deficient; PrtB protease deficient; Prc protease deficient; DegP protease deficient; AprA protease deficient; Lon protease deficient; La protease deficient; DegP1 deficient; DegP2 deficient; DegP S219A overexpressing; or a combination thereof.

Images